November 10, 2020 Curriculum Vitae

Amit Segev MD – Curriculum Vitae

of 93

November 10, 2020

Curriculum Vitae

Prof. Amit Segev, MD, FESC, FACC

I.D. Number: 02264753-1

Israeli Medical License Number: 26326

Address (home):

37 Tshernichovsky Street, Ra'anana 4336917, Israel

Address (work):

Director, Division of Cardiology

The Heart Center, Chaim Sheba Medical Center

Tel-Hashomer, 52621, Israel

(Affiliated to Sackler School of Medicine, Tel-Aviv University, Isreal)

Tel (home): +972-9-7431442

Mobile: +972-52-6667581

Tel (Hospital): +972-3-5302606

Fax (Hospital): +972-3-5307556

E-mail: [email protected] and [email protected]

Date and place of birth: August 6, 1966, Tel-Aviv, Israel

Marital status: Married to Fani + 4 daughters (Lior, Mai, Aviv, Tal)

mailto:[email protected]

mailto:[email protected]


of 93

A. EDUCATION Medical School:

1984-1991: Faculty of Medicine – Technion, Israel Institute of Technology,

Haifa, Israel – Academic Reserve Program

Degrees & Licenses:

B.Sc. in Medical Sciences (with honor) - 1988

Medical Doctor (MD) – 1992

ECFMG (USMLE) Certificate: Number 0-458-861-2 (September, 1998)

Specialist in Internal Medicine – 2000 (license number: 17926)

Specialist in Cardiology – 2003 (license number: 20659)

4 semesters in Continuing Medical Education (CME) in cardiology, Tel Aviv

University – 2000/1

Clinical Interventional Cardiology Fellowship, St. Michael’s Hospital, University

of Toronto, Toronto, Ontario, Canada – 2002 – 2004

FESC – Fellow of the European Society of Cardiology – June 2008

FACC – Fellow of the American College of Cardiology – December 2013


of 93

C. ACADEMIC AND PROFFESIONAL EXPERIENCE

Rotating Internship (1991-1992): Rambam Medical Center, Haifa, Israel

Army Service

o Israeli Defense Forces (IDF) battalion and brigade medical officer (1992-

1994)

o Head of IDF Golan Heights Medical Center (1994-1996)

o Highest rank - Major

Residency in Internal Medicine (1996-1999): Department of Internal Medicine

B, Meir General Hospital, Kfar-Saba, Sackler School of Medicine, Tel Aviv

University, Israel

Basic Sciences Research period (1998): Department of Molecular Cell Biology,

Weizmann Institute of Science, Rehovot, Israel

Passed the 1st stage examination of the Israel Scientific Council in Internal

Medicine – 1999

Passed the 2nd stage examination of the Israel Scientific Council in Internal

Medicine – 1999

Residency in Cardiology (1999–2002): Department of Cardiology, Meir

General Hospital, Kfar-Saba, Sackler School of Medicine, Tel Aviv University,

Israel

Passed the 1st stage examination of the Israel Scientific Council in Cardiology –

2001

Passed the 2nd stage examination of the Israel Scientific Council in Cardiology

– 2001

Fellowship in Interventional Cardiology & Basic Cardiovascular Research

(2002–2004): Terrence Donnelly Heart Center, The Roy and Ann Foss

Cardiovascular Research Program and Interventional Cardiology Program, St.

Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada

Staff (Senior) Cardiologist (from 2004): Interventional Cardiology Unit, The

Heart Institute, Chaim Sheba Medical Centre, Tel-Hashomer, Affiliated to Tel-

Aviv University, Israel


of 93

Coordinator, CME Cardiology Course – Sackler School of Medicine, Tel Aviv

University. 2006-2009.

Member, Committee for cardiology final examinations, Israel Heart Society.

2007-2009.

Treasurer, Isreali Working Group in Interventional Cardiology, Israel Heart

Society. 2009-2011

Senior Lecturer (Assistant Professor) in Cardiology – Sackler School of

Medicine, Tel-Aviv University, Tel-Aviv, Israel - from 2009

Coordinator, Cardio-Vascular System Education and Course for 2nd year

medical students – 4-year Program, Sackler School of Medicine, Tel-Aviv

University – 2008-2013

Secretary General, The Israel Heart Society – 2011-2015

Scientific Committee member, The Elizabeth and Nicholas Slezak Super Center

for Cardiac Research and Medical Engineering – Tel-Aviv University – 2012-

present

Deputy Director, The Heart Institute, Chaim Sheba Medical Center, Tel

Hashomer, affiliated to Sackler School of Medicine, Tel Aviv University, Israel –

2013-2016

Director, Cardiac Catheterization Services, The Heart Institute, Chaim Sheba

Medical Center, Tel Hashomer, affiliated to Sackler School of Medicine, Tel Aviv

University, Israel – 2013-2016

Member of the European Society of Cardiology (ESC) Credentials Committee –

from 2014

Committee Chair – My national society at ESC Congress – London, UK - 2015

Associate Professor of Cardiology- Sackler School of Medicine, Tel-Aviv

University, Tel Aviv, Israel – from 2014

Director, Division of Cardiology, Chaim Sheba Medical Center, Tel Hashomer,

affiliated to Sackler School of Medicine, Tel Aviv University, Israel – from Feb

2016


of 93

Member of the Congress Program Committee (CPC) of the European Society of

Cardiology – 2016-2018

Committee member – Talpiot Excellence Program, Chaim Sheba Medical

Center, Tel Hashomer, Israel

Committee member – Clinical Research Ethics Committee (Helsinki), Chaim

Sheba Medical Center, Tel Hashomer, Israel

Committee member – Residency programs in Medicine – Israel Medical

Scientific Council, Israel Medical Association – 2018-2019

Member of the Congress Program Committee – EAPCI – from 2020


of 93

D. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS

1. American Heart Association (AHA), 71st Scientific Sessions, 1998, Dallas, TX,

USA (Abstract presenter)

2. American College of Cardiology (ACC), 51st Annual Scientific Sessions, 2002,

Atlanta, GA, USA (Abstract presenter)

3. American Heart Association (AHA), 75th Scientific Sessions, 2002, Chicago, IL,


4. Interventional Cardiology Fellows Course (Cardiovascular Research

Foundation), 2003, San Jose, CA, USA

5. American Heart Association (AHA), 76th Scientific Sessions, 2003, Orlando, FL,


6. Transcatheter Cardiovascular Therapeutics (TCT), 2003, Washington, DC, USA

(Faculty member)

7. Canadian Cardiovascular Society Congress (CCSC), 2003, Toronto, ON, Canada

(Abstract presenter)

8. 5th International Meeting on Interventional Cardiology: Frontiers in

Interventional Cardiology, 2003, Tel-Aviv, Israel (Abstract presenter)

9. American College of Cardiology (ACC), 53rd Annual Scientific Sessions, 2004,

New Orleans, LA, USA (Abstract presenter)

10. Interventional Cardiology Fellows Course (Cardiovascular Research

Foundation), 2004, San Jose, CA, USA


(Faculty member, case presenter)

12. American Heart Association (AHA), 77th Scientific Sessions, 2004, New

Orleans, LA, USA (Abstract presenter)

13. Global Cardiovascular Interventions (GCI), 2004, Frankfurt, Germany (Faculty

member, Presenter)

14. 6th International Meeting on Interventional Cardiology: Frontiers in

Interventional Cardiology, 2004, Tel-Aviv, Israel (Presenter)


(Faculty Member, Presenter)


of 93

16. EUROPCR, 2006, Paris, France (Faculty member, Presenter)


(faculty member, Presenter)

18. EUROPCR, 2007, Barcelona, Spain (Faculty Member, Presenter)



(Faculty member, Presenter)

21. Innovations in Cardiovascular Interventions (ICI), 2008, Tel-Aviv, Israel (Chair

of session)


23. Montreal Interventional Cardiology Meeting, 2009, Montreal, Canada

(Presenter, Panelist)

24. Horizons in Invasive Cardiology, 2009, Rambam Medical Center, Haifa, Israel

(Panelist)

25. Transcatheter Cardiovascular Therapeutics (TCT), 2009, San Francisco, CA, USA

(Faculty Member, Presenter)

26. Innovations in Cardiovascular Interventions (ICI), 2009, Tel-Aviv, Israel

(Chairmen of session)

27. 7th International Chronic Total Occlusion Summit, February 2010, New York,

NY, USA (Faculty Member, Presenter)

28. 57th Annual Conference of the Israel Heart Society, April 2010, Tel Aviv, Israel

(Chairman of session, Reviewer of abstracts)

29. EUROPCR, June 2010, Paris, France (Faculty Member, Presenter)

30. Montreal Interventional Cardiology Meeting, June 2010, Montreal, Canada

(Presenter, Panelist)


(Panelist)

32. Transcatheter Cardiovascular Therapeutics (TCT), September 2010,

Washington, DC, USA (Faculty Member, Presenter, Panelist)

33. Biotronik Focus Group, 2010, Zurich, Switzerland (Presenter, Discussant)

34. Innovations in Cardiovascular Interventions (ICI), December 2010, Tel-Aviv,

Israel (Chairmen of session, Operator – live cases)


of 93

35. Cardiovascular Research Technologies Meeting (CRT), February 2011,

Washington, DC, USA (Faculty member, Chairman of session, Presenter)


(Reviewer of abstracts, Presenter)

37. India Live 2011 (interventional cardiology meeting), February 2011, Mumbai,

India (Faculty member, Chairman of session)

38. TCT Meditereanean, March 2011, Antalya, Turkey (Live case operator)


(Panelist)

40. ESC Congress, August 2011, Paris, France (Secretary General of IHS)

41. 2nd Transradial Workshop in Transradial Intervention, September 2011,

Jerusalem, Israel (Faculty member, Presenter)

42. International Summit on Imaging and Intervention in Cardiology (ISIIC),

September 2011, Katowice, Poland (Presenter, Faculty member, Panelist)

43. Transcatheter Cardiovascular Therapeutics (TCT), November 2011, San

Fransisco, CA, USA (Faculty Member, Panelist, Reviewer of abstracts)

44. 9th International Congress on Coronary Artery Disease (ICCAD), October 2011,

Venice, Italy (Reviewer of abstracts)


Israel (Faculty member, Presenter)

46. American College of Cardiology (ACC.12), Annual Scientific Sessions, March

2012, Chicago, IL, USA (Faculty member, presenter, Panelist)


(Main Organizer, Chair, Reviewer of abstracts)

48. The 61st International Congress of The European Society of Cardiovascular and

Endovascular Surgery – ESCVS, 2012, Dubrovnik, Croatia (Faculty member,

Presenter).

49. EUROPCR, May 2012, Paris, France (Faculty Member, Presenter)

50. The 1st International Heart Valve Summit of the Israel Heart Society, May 2012,

Jerusalem, Israel (Organizing Committee)


(Panelist)


of 93

52. ESC Congress, August 2012, Munich, Germany (Secretary General of IHS,

Abstract Presenter)

53. Transcatheter Cardiovascular Therapeutics (TCT), October 2012, Miami, FL,

USA (Faculty Member, Panelist, Reviewer of abstracts)


Israel (Faculty member, scientific committee, abstract reviewer, panelist,

Presenter)

55. French Society of Cardiology Annual Meeting, January 2013, Paris, France

(Faculty member, Presenter)


2013, San Francisco, CA, USA (Faculty member, Presenter, Panelist)

57. The IV Congress of Surgeons of the Republic of Kazakhstan, April 2013, Almaty,

Kazakhstan (Lecturer)

58. 60th Annual International Conference of the Israel Heart Society, April 2013,

Jerusalem, Israel (Main Organizer, Chair, Reviewer of abstracts)

59. 8th International Congress on Acute Cardiac Care, June 2013, Jerusalem, Israel

(Faculty, Presenter)

60. ESC Congress, August 2013, Amsterdam, The Netherlands (Reviewer of

abstracts, Presenter, Faculty member)

61. 50th Congress of the Russian Society of Cardiology, September 2013, St.

Petersburg, Russia (Invited speaker)

62. VIVA, October 2013, Las Vegas, NE, USA (Faculty member, Presenter)

63. 10th International Congress on Coronary Artery Disease (ICCAD), October

2013, Florence, Italy (Invited speaker, Faculty member, Reviewer of abstracts)


Francisco, CA, USA (Faculty Member, Panelist, Presenter, Reviewer of

abstracts)

65. French Society of Cardiology Annual Meeting, January 2014, Paris, France

(Invited speaker)


2014, Washington, DC, USA (Reviewer of abstracts, abstract presenter)


of 93

67. 61st Annual Conference of the Israel Heart Society, April 2014, Tel Aviv, Israel

(Main Organizer, Chair, Reviewer of abstracts)

68. ESC Congress, August 2014, Barcelona, Spain (Faculty member, abstract

reviewer, abstract presenter, chair of session)

69. GISE, Annual Meeting of the Italian Society of Invasive Cardiology, October

2014, Genoa, Italy (Invited speaker)

70. 5th Angol-Israel Cardiovascular Symposium, October 2014. London, England

(Invited speaker)

71. VIVA, November 2014, Las Vegas, NE, USA (Faculty member, presenter)

72. American Heart Association Scientific Sessions, November 2014, Chicago, IL,

USA (Faculty member, presenter)


Israel (Faculty member, scientific committee, Presenter)

74. 9th International Conference on Acute Cardiac Care, January 2015, Tel Aviv,

Israel (Faculty, speaker)

75. Cardiovascular Research Technologies Meeting (CRT), February 2015,

Washington, DC, USA (Faculty member, Presenter, Abstract reviewer)


2015, San Diego, CA, USA (Reviewer of abstracts, Faculty member, speaker)

77. China Interventional Therpeutics (CIT), March 2015. Beijing, China (Invited

speaker)

78. 62nd Annual Conference of the Israel Heart Society, April 2015, Tel Aviv, Israel

(Main organizer)

79. China Innovation in Cardiology (CIC), June 2015, Nanjing, China (Invited

speaker, panelist)

80. ESC Congress, August 2015, London, UK (Faculty member, abstract reviewer,

Invited speaker, committee member)


Francisco, CA, USA (Faculty Member, Panelist, Reviewer of abstracts)

82. 11th International Congress on Coronary Artery Disease (ICCAD), November

2015, Florence, Italy (Invited speaker, Faculty member, Reviewer of abstracts)


of 93



84. Heart Valve Society Annual Meeting, March 2016, New York, NY, USA (Invited

speaker)


2016, Chicago, IL, USA (Reviewer of abstracts, Faculty member, speaker)

86. 2nd Conference of Israel Society of Resuscitation, May 2016, Ramat Gan, Israel

(Invited speaker)

87. MEDICO 2016, May 2016, Tel Aviv, Israel (Session chair and organizer, invited

speaker)

88. EuroPCR 2016, May 2016, Paris, France (Invited speaker)

89. ESC Congress 2016, August 2016, Rome, Italy (faculty, invited speaker,

reviewer of abstracts)

90. PCR London Valves, September 2016, london, UK (invited speaker)

91. Annual Meeting of the Romanian Society of Cardiology, September 2016,

Sinaia, Romania (invited speaker)

92. Annual Meeting of the Acute Cardiac Care Association, October 2016, Lisbon,

Portugal (Faculty, Reviewer of abstracts, Invited speaker)

93. Transcatheter Cardiovascular Therapeutics (TCT), November 2016,

Washington, DC, USA (Reviewer of abstracts)



95. 10th International Conference on Acute Cardiac Care, January 2017, Tel Aviv,

Israel (Faculty, speaker)

96. ESC Congress 2017, August 2017, Barcelona, Spain (Program committee,

faculty, invited speaker, reviewer of abstracts)

97. Transcatheter Cardiovascular Therapeutics (TCT), October 2017, Denver, CO,

USA (Faculty Member, Panelist, Reviewer of abstracts)




2018, Orlando, FL, USA (Reviewer of abstracts, Faculty member)


of 93

100. Transcatheter Cardiovascular Therapeutics (TCT) Russia, May 2018,

Moscow, Russia (Invited speaker, session chair)

101. 11th International Conference on Acute Cardiac Care, June 2018, Tel

Aviv, Israel (Faculty, speaker)

102. ESC Congress 2018, August 2018, Munich, Germany (Program

committee, faculty, invited speaker, reviewer of abstracts)

103. Transcatheter Cardiovascular Therapeutics (TCT), September 2018,

San Diego, CA, USA (Faculty Member, Panelist)

104. IX New Frontiers in Cardiovascular Medicine Congress, February 2019,

Lisbon, Portugal (Invited speaker)

105. American College of Cardiology (ACC.19), Annual Scientific Sessions,

March 2019, New Orleans, LO, USA (Faculty member, invited speaker)

106. Innovations in Cardiovascular Interventions (ICI), December 2019, Tel-

Aviv, Israel (Faculty member, scientific committee, Presenter)


of 93

E. ACADEMIC AND PROFESSIONAL AWARDS

1) Ranked the 1st in a sociometric evaluation survey among all officers in Barak

Brigade Central Command (≈40 officers), Israeli Defense Forces (IDF) – 1993

2) Under my command, Golan Heights Medical Center was awarded as the best clinic

in the Israeli Defense Forces (IDF) – 1995

3) Ranked the 1st in a sociometric evaluation survey among all officers in the 541

Medical Unit of the Northern Command (≈50 officers), Israeli Defense Forces (IDF)

- 1995

4) Meir Hospital General Manager Award for a best residency research (3000 US$) –

November 1998

5) Yael Foundation Research Grant, Israel. Principal Investigator. Inhibition of

vascular smooth muscle cell proliferation by a novel class of fibroblast growth

factor receptor antagonists. (50,000 US$) – December 1998 – November 2000.

6) Awarded as best teacher by 4-6th year medical students, Meir Hospital, Tel-Aviv

University, 2001/2

7) Merck, Sharp & Dome (MSD) Fellowship Award – Israel Heart Society (10,000

US$) – April 2002

8) “Reut” Foundation Fellowship Grant, Israel (10,000US$) – September 2002

9) Heart and Stroke Foundation of Canada Research Fellowship Award, the role of

adventitial angiogenesis in the arterial response to injury – (50,000 CA$/year) –

July 2003 – December 2004

10) Department of Medicine - University of Toronto Research Award, Canada

(20,000 CA$/year) – 2003/4

11) The Edie Steinberg Scholarship Fund, Edward Christie Stevens Fellowship and

the Nellie L. Farthing Fellowship, Postgraduate Medicine Awards Committee of

the Faculty of Medicine, University of Toronto, Ontario, Canada (6,950 CA$) –

2003/4.

12) Finalist in a poster competition in clinical sciences. American Heart Association

(AHA), 76th Scientific Sessions, Nov 2003, Orlando, FL, USA.


of 93

13) Best Abstract Award winner (1000US$), 5th International Meeting on

Interventional Cardiology: Frontiers in Interventional Cardiology, Dec 2003, Tel-

Aviv, Israel.

14) Kachel E, Kassif Y, Raanani E, Strauss BH, Segev A. Positive Remodeling in Venous

Bypass Grafts: Novel Implications for Vein Graft Disease. Ami Cohen Award

Finalist. The 54th Annual Meeting of The Israel Heart Society, 2007, Tel-Aviv, Israel

15) Amsalem Y, Guetta V, Laish-Farkash A, Segev A. Comparison of Late versus Early

Stent Thrombosis: 5-Year Experience from a Large Unselected Population. Elad

Grenadier Memorial Best Abstract Award. Horizons in Interventional Cardiology,

2008, Haifa, Israel

16) Best Tutor in Cardiology - 2008, Sackler School of Medicine, Tel-Aviv University,

Tel-Aviv, Israel

17) Segev A, Nili N, Osheov AB, Qiang B, Wong AJ, Pillarisetti S, Strauss BH. A Perlecan-

Inducing Compound Significantly Inhibits Smooth Muscle Cell Function and In-

stent Intimal Hyperplasia - Novel Insights into the Diverse Biological Effects of

Perlecan. Awarded as 5 of the best publications of the year in EuroIntervention.

Presented at EUROPCR, Paris, France. May 2010

18) Cardiovascular Research Technologies (CRT) Young Leadership Program Award.

Washington, DC, USA. February 2011.

19) Goldenberg G, Segev A, Dvir D, Kornowski R, Finkelstein A, Hay I, Glikson M,

Guetta V. Predictors and course of high-degree atrioventricular block after

transcatheter aortic valve implantation using the CoreValve revalving system. Elad

Grenadier Memorial Best Abstract Award. Horizons in Interventional Cardiology,

2011, Haifa, Israel

20) Best Teacher in Cardiology - 2011, Sackler School of Medicine, Tel-Aviv University,

Tel-Aviv, Israel

21) Maor E, Balmor R, Grossman Y, Segel M, Fefer P, Ben-Zekry S, Buber J, DiSegni E,

Guetta V, Ben-Dov I Segev A. Exercise hemodynamics may unmask the diagnosis

of diastolic dysfunction among patients with pulmonary hypertension. Highest

ranking abstract submitted from praticipating Middle East countries and accepted

for presentation at the ACC Annual Scientific Sessions, ACC.14, 2014, Washington,

DC, USA

http://www.ncbi.nlm.nih.gov/pubmed/21880290



of 93


Guetta V, Ben-Dov I, Segev A. Exercise Hemodynamics may Enhance the Diagnosis

of Diastolic Dysfunction Among Patients with Pulmonary Hypertension. Ian

Kellerman Young Investigator Award Finalist. 61st Annual Meeting of the Israel

Heart Society, April 2014, Tel Aviv, Israel


Guetta V, Ben-Dov I Segev A. Exercise hemodynamics may unmask the diagnosis

of diastolic dysfunction among patients with pulmonary hypertension. Eur J Heart

Fail. Best publication award. 62nd Annual Meeting of the Israel Heart Society, April

2015, Tel Aviv, Israel

24) The Michael Mirowski Excellence in Cardiology Award. 65th Annual Meeting of

the Israel Heart Society, April 2018, Tel Aviv, Israel

25) Segev A, Heler E, Maor E. Electroporation-based platform for trans-catheter

cardiac interventions. Research Grant from The Elizabeth and Nicholas Slezak

Super Center for Cardiac Research and Medical Engineering – Tel-Aviv University

– 2019 (100,000 NIS)


of 93

F. MEMBERSHIPS IN PROFESSIONAL SOCIETIES 1) Israel Medical Association

2) Israel Heart Society

3) The College of Physicians and Surgeons of Ontario (CPSO) (2002-2004)

4) Canadian Cardiovascular Society (CCS) (2002-2004)

5) Europeran Association of Percutaneous Cardiovascular Interventions (EAPCI)

6) FESC – Fellow of the European Society of Cardiology

7) European Association of Acute Cardiovascular Care (EAACC)

8) FACC – Fellow of the American College of Cardiology


of 93

SCIETIFIC PUBLICATIONS PEER-REVIEWED PAPERS:

B.1. ORIGINAL ARTICLES – PUBLISHED AND ACCEPTED:

1) Aviezer D, Cotton S, David M, Segev A, Khaselev N, Galili N, Gross Z, Yayon A.

Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular

endothelial growth factor receptor binding that inhibit endothelial cell proliferation,

tumor progression and metastases.

Cancer Res 2000, 60:2973-2980 (ONCLOLGY 21/229 IF 8.378, cited 172)

2) Niv E, Segev A, Ellis MH.

Staphylococcus aureus bacteremia as a cause of early relapse of thrombotic

thrombocytopenic purpura.

Transfusion 2000, 40:1067-70 (HEMATOLOGY 29/73, IF 3.111, cited 21)

3) Segev A, Aviezer D, Safran M, Gross Z, Yayon A.

Inhibition of vascular smooth muscle cell proliferation by a novel class of fibroblast

growth factor receptor antagonist.

Cardiovasc Res 2002, 53:232-241 (CARDIAC & CARDIOVASCULAR SYSTEMS 12/136,

IF 7.014, cited 55)

4) Strauss BH, Goldman L, Qiang B, Nili N, Segev A, Butany J, Sparkes JD, Jackson ZS,

Eskandarian MR, Virmani R.

Collagenase plaque digestion for facilitating guidewire crossing in chronic total arterial

occlusions.

Circulation 2003, 108:1259-1262 (CARDIAC & CARDIOVASCULAR SYSTEMS 2/136, IF

23.054, cited 64)

5) Lau HK, Segev A*, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH.

Thrombin-activatable fibrinolysis inhibitor (TAFI): A novel predictor of angiographic

coronary restenosis.


of 93

Thromb Haemost 2003, 60:1217-1221. *First two authors contributed equally

(HEMATOLOGY 15/79, IF 4.733, cited 35)

6) Daoulah A, Segev A, Leblanc K, Chisholm RJ, Strauss BH.

Post-procedural low molecular weight heparin in patients at high risk of subacute

stent thrombosis.

Cardiovasc Radiat Med 2003, 4:182-185. (CARDIAC & CARDIOVASCULAR SYSTEMS,

not listed, cited 11)

7) Segev A, Kassam S, Buller CE, Lau HK, Sparkes JD, Seidelin PH, Natarajen MK, Cohen

EA, Strauss BH.

Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict

late coronary angiographic restenosis after stenting.

Eur Heart J 2004, 25:1029-35. (CARDIAC & CARDIOVASCULAR SYSTEMS 1/136, IF

23.239, cited 67)

8) Segev A, Cantor WJ, Cohen EA, Seidelin PH, Natarajan MK, Marquis JF, Lazzam C,

Watson RK, Chisholm RJ, Strauss BH.

Low rates of angiographic and clinical restenosis with the new flexible MedStent for

the treatment of single discrete coronary lesions.

J Interven Cardiol 2004, 17:167-170. (CARDIAC & CARDIOVASCULAR SYSTEMS,

77/136, IF 2.106)

9) Tsimikas S, Lau HK, Han KR, Shortal B, Miller E, Segev A, Curtiss LK, Witztum JL,

Strauss BH.

Percutaneous coronary intervention results in acute increases in oxidized

phospholipids and Lp(a): acute and long-term immunological responses to oxidized

LDL.

Circulation, 2004, 109:3164-70. (CARDIAC & CARDIOVASCULAR SYSTEMS 2/136, IF

23.054, cited 226)

10) Qiang B, Segev A, Beliard I, Nili N, Strauss BH, Sefton MV.


of 93

Poly(methylidene malonate 2.1.2) nanoparticles: a biocompatioble polymer that

enhances peri-adventitial adenoviral gene delivery.

J Control Release, 2004, 98:447-455. (PHARMACOLOGY & PHARMACY 9/360, IF

7.877, cited 15)

11) Segev A, Goldman LE, Cantor WJ, Barr A, Strauss BH, Winegard LD, Bowman KA,

Chisholm RJ.

Elevated troponin-I after percutaneous coronary interventions: incidence and risk

factors.

Cardiovasc Radiat Med 2004, 5:59-63. (CARDIAC & CARDIOVASCULAR SYSTEMS, not

listed, cited 11)

12) Segev A, Hegele RA, Lau HK, Sparkes JD, Chisholm RJ, Strauss BH.

Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and

angiographic restenosis after percutaneous coronary interventions.

Thromb Res 2004, 114:135-139. (HEMATOLOGY 27/79, IF 3.266, cited 23)

13) Segev F, Mor O, Segev A, Belkin M, Assia EI.

Downregulation of gene expression in the ageing lens: a possible contributory factor

in senile cataract.

Eye 2005, 19:80-5. (OPHTHALMOLOGY 21/59, IF 2.366, cited 30)

14) Segev A, Ellis MH, Segev F, Friedman Z, Reshef T, Tetro J, Pauzner H, David D.

High prevalence of thrombophilia markers among young patients with myocardial

infarction and few conventional risk factors.

Int J Cardiol 2005, 98:421-424. (CARDIAC & CARDIOVASCULAR SYSTEMS 48/136, IF

3.471, cited 59)

15) Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG.

Predictors and long-term outcome of major bleeding in patients with non-ST elevation

acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome

Registries.

http://www.ncbi.nlm.nih.gov/pubmed?term=Segev%20F%5BAuthor%5D&cauthor=true&cauthor_uid=15105821

http://www.ncbi.nlm.nih.gov/pubmed?term=Mor%20O%5BAuthor%5D&cauthor=true&cauthor_uid=15105821

http://www.ncbi.nlm.nih.gov/pubmed?term=Segev%20A%5BAuthor%5D&cauthor=true&cauthor_uid=15105821

http://www.ncbi.nlm.nih.gov/pubmed?term=Belkin%20M%5BAuthor%5D&cauthor=true&cauthor_uid=15105821

http://www.ncbi.nlm.nih.gov/pubmed?term=Assia%20EI%5BAuthor%5D&cauthor=true&cauthor_uid=15105821

http://www.ncbi.nlm.nih.gov/pubmed?term=segev%20a%20eye


of 93

Am Heart J 2005, 150:690-694. (CARDIAC & CARDIOVASCULAR SYSTEMS 41/136, IF

4.023, cited 123)

16) Segev A, Strauss BH, Witztum JL, Lau HK, Tsimikas S.

Relationship of a comprehensive panel of plasma OxLDL markers to angiographic

restenosis in patients undergoing percutaneous coronary intervention for stable

angina.

Am Heart J 2005, 150:1008-1015. (CARDIAC & CARDIOVASCULAR SYSTEMS 41/136 IF

4.023, cited 27)

17) Segev A, Nili N, Qiang B, Charron T, Butany J, Strauss BH.

Human-grade purified collagenase for the treatment of experimental chronic total

occlusions.

Cardiovasc Revasc Med 2005, 6:65-69. (CARDIAC & CARDIOVASCULAR SYSTEMS, not

listed, cited 26)

18) Cheema AN, Hong T, Nili N, Segev A, Moffat JG, Lipson KE, Howlett AR, Holdsworth

DW, Cole M, Qiang B, Kolodgie F, Virmani R, Stewart DJ, Strauss BH.

Adventitial angiogenesis: a novel mechanism of in-stent restenosis and inhibitory

effects of SU11218, a tyrosine kinase inhibitor.

J Am Coll Cardiol 2006;47:1067-75. (CARDIAC & CARDIOVASCULAR SYSTEMS 3/136,

IF 18.639, cited 48)

19) Strauss BH, Segev A, Wright GA, Qiang B, Munce N, Anderson KJT, Leung G, Dick

AJ, Virmani R, Butany J.

Microvessels in chronic total occlusions: pathway for successful guide-wire crossing?

J Interven Cardiol 2005;18:425-36. (CARDIAC & CARDIOVASCULAR SYSTEMS, 77/136,

IF 2.106, cited 47)

20) Elian D, Guetta V, Alcalai R, Lotan C, Segev A.

Early mobilization after diagnostic cardiac catheterization with the use of a hemostatic

bandage containing thrombin.


of 93

Cardiovasc Revasc Med 2006;7:61-3. (CARDIAC & CARDIOVASCULAR SYSTEMS, not

listed, cited 5)

21) Segev A, Strauss BH, Tan M, Mendelsohn AA, Lai K, Ashton T, Fitchett D, Grima E,

Langer A, Goodman SG.

Prognostic significance of admission heart failure in patients with non ST-elevation

acute coronary syndrome - from the Canadian Acute Coronary Syndrome Registries.

Am J Cardiol 2006; 98:45-48. (CARDIAC & CARDIOVASCULAR SYSTEMS 59/136, IF

2.843, cited 38)

22) Segev A, Cantor WJ, Strauss BH.

Outcome of percutaneous coronary interventions in HIV-infected patients

Catheter Cardiovasc Interv 2006;86:879-81. (CARDIAC & CARDIOVASCULAR SYSTEMS

64/136, IF 2.551, cited 24)

23) Segev A, Strauss BH, Tan M, Buller CE, Mendelsohn AA, Langer A, Goodman SG.

Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST

elevation acute coronary syndrome.

Int J Cardiol 2008;129:233-7 (CARDIAC & CARDIOVASCULAR SYSTEMS 48/136, IF

3.471, cited 1)

24) Segev A, Elian D, Marai I, Matetzky S, Agranat O, Har-Zahav Y, Guetta V. Thrombus

aspiration during primary percutaneous coronary intervention in acute ST-elevation

myocardial infarction.

Cardiovasc Revasc Med 2008;9:140-3. (CARDIAC & CARDIOVASCULAR SYSTEMS, not

listed, cited 9)

25) Fefer P, Hod H, Ilany J, Shechter M, Segev A, Novikov I, Guetta V, Matetzky S.

Comparison of myocardial reperfusion in patients with fasting blood glucose < or

=100, 101 to 125, and >125 mg/dl and ST-elevation myocardial infarction with

percutaneous coronary intervention.

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Fefer%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Hod%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ilany%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shechter%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Segev%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Novikov%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Guetta%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Matetzky%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus


of 93

Am J Cardiol 2008;102:1457-62. (CARDIAC & CARDIOVASCULAR SYSTEMS 59/136, IF

2.843, cited 17)

26) Parikh KH, Shah A, Chag MC, Segev A.

Ovalum CiTop™ Expander™: A novel guidewire for crossing coronary chronic total

occlusions – First-in-Man experience.

EuroIntervention 2009;5:206-11. (CARDIAC & CARDIOVASCULAR SYSTEMS 42/136, IF

4.018, cited 1)

27) Segev A, Fefer P, Strauss BH, Matetzky S, Tan M, Langer A, Goodman SG.

Outcome of patients with acute coronary syndromes enrolled in clinical trials.

Cor Art Dis 2009;20(7):473-476. (CARDIAC & CARDIOVASCULAR SYSTEMS 104/136, IF

1.554, cited 1)

28) Fefer P, Hod H, Hammerman H, Segev A, Beinart R, Boyko V, Behar S, Matetzky S.

Usefulness of pretreatment with high-dose clopidogrel in patients undergoing

primary angioplasty for ST-elevation myocardial infarction.

Am J Cardiol 2009;104(4):514-8. (CARDIAC & CARDIOVASCULAR SYSTEMS 59/136, IF

2.843, cited 33)

29) Segev A, Nili N, Osherov AB, Qiang B, Wong AJ, Pillarisetti R, Strauss BH.

Perlecan-inducing compound significantly inhibits smooth muscle cell function and in-

stent intimal hyperplasia - novel insights into the diverse biological effects of perlecan.

EuroIntervention 2010;6(1):134-40. (CARDIAC & CARDIOVASCULAR SYSTEMS 42/136,

IF 4.018, cited 2)

30) Beinart R, Abu Sham'a R, Segev A, Hod H, Guetta V, Shechter M, Boyko V, Behar S,

Matetzky S.

The incidence and clinical predictors of early stent thrombosis in patients with acute

coronary syndrome.

javascript:AL_get(this,%20'jour',%20'Am%20J%20Cardiol.');

http://www.ncbi.nlm.nih.gov/pubmed/19660604?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

http://www.ncbi.nlm.nih.gov/pubmed/19660604?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1




of 93

Am Heart J 2010;159(1):118-24. (CARDIAC & CARDIOVASCULAR SYSTEMS 39/128, IF

4.171, cited 24)

31) Danenberg H, Finkelstein A, Kornowski R, Segev A, Dvir D, Gilon D, Keren G, Sagie

A, Feinberg M, Schwammenthal E, Banai S, Lotan C, Guetta V.

Percutaneous implantation of the self-expandable CoreValve for high-risk patients

with severe aortic valve stenosis: early Israeli experience.

Isr Med Assoc J 2010;12:468-471. (MEDICINE, GENERAL & INTERNAL 114/154, IF

0.817, cited )

32) Charron T, Jaffe R, Segev A, Bang KWA, Qiang B, Sparkes JD, Butany J, Dick AJ,

Freedman J, Strauss BH.

Effects of distal embolization on the timing of platelet and inflammatory cell activation

in interventional coronary no-reflow.

Thromb Res 2010;126:50-55 (HEMATOLOGY 27/79, IF 3.266, cited 24)

33) Fefer P, Daoulah A, Strauss BH, Chisholm RJ, Sparkes JD, Segev A.

Visible angiographic complications predict short and long-term outcomes in patients

with post-procedural creatine-phosphokinase elevation.

Catheter Cardiovasc Interv 2010;76:960-6 (CARDIAC & CARDIOVASCULAR SYSTEMS

60/128, IF 2.602, cited 9)

34) Segev A, Nili N, Qiang B, Osherov AB, Giordano F, Jaffe R, Gauldie J, Sparkes JD,

Fraser AR, Ladouceur-Wodzak M, Butany J, Strauss BH.

Inhibition of neo-intimal hyperplasia after stenting by over-expression of p15 – a

memeber of the INK4 family of CDK inhibitors.

J Mol Cell Cardiol 2011;50:417-25 (CARDIAC & CARDIOVASCULAR SYSTEMS 23/128,

IF 5.296, cited 5)

35) Hamdan A, Guetta V, Konen E, Goitein O, Segev A, Raanani E, Spiegelstein D, Hay

I, DiSegni E, Eldar M, Schwammenthal E.


of 93

Deformation dynamics and mechanical properties of the aortic annulus by four-

dimensional computed tomography - Insights into the functional anatomy of the aortic

valve complex and implications for transcatheter aortic valve therapy.

J Am Coll Cardiol 2012;59:119-27 (CARDIAC & CARDIOVASCULAR SYSTEMS 3/128, IF

16.834, cited 140)

36) Guetta V, Goldenberg G, Segev A, Dvir D, Kornowski R, Finkelstein A, Hay I,

Goldenberg I, Glikson M.

Predictors and course of high-degree atrioventricular block after transcatheter aortic

valve implantation using the CoreValve revalving system.

Am J Cardiol 2011;108:166-5. (CARDIAC & CARDIOVASCULAR SYSTEMS 49/128, IF

3.171, cited 81)

37) Fefer P, Tsimikas S, Segev A, Lau H, Sparkes J, Otsuma F, Kolodgie F, Virmani R,

Charron T, Strauss BH.

The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized

lipoproteins in chronically occluded coronary arteries following successful

percutaneous revascularization.

Cardiovasc Revasc Med, 2011;13:11-9 (CARDIAC & CARDIOVASCULAR SYSTEMS, not

listed, cited 21)

38) Segev A, Beigel R, Goitein O, Brosh S, Oiero D, Konen E, Hod H, Matetzky S.

Non-obstructive coronary artery disease upon multi-detector computed tomography

in patients presenting with acute chest pain - Results of an intermediate term follow-

up.

Eur Heart J Cardiovac Imaging, 2012;13;169-73 (CARDIAC & CARDIOVASCULAR

SYSTEMS 10/128, IF 8.336, cited 10)

39) Jaffe R, Finkelstein A, Lewis BS, Guetta V, Khader N, Halon DA, Segev A.

Stenting of the unprotected left main coronary artery in patients with severe aortic

stenosis prior to percutaneous valve interventions




of 93

Cardiovasc Revasc Med, 2012;13:90-4 (CARDIAC & CARDIOVASCULAR SYSTEMS, not

listed, cited 12)

40) Segev A, Matetzky S, Danenberg H, Bubyr L, Zahger D, Roguin A, Gottlieb S,

Kornowski R; for the ACSIS and ACSIS-PCI 2010 investigators

Contemporary use and outcome of percutaneous coronary interventions in patients

with acute coronary syndromes: Insights from 2010 ACSIS and ACSIS-PCI Registries.

EuroIntervention, 2012;8:465-9 (CARDIAC & CARDIOVASCULAR SYSTEMS 37/128, IF

4.417, cited 13)

41) Ben-Dov I, Kogan A, Preisman S, Rimon U, Segev A, Schafers JH.

Chronic thromboembolic pulmonary hypertension: can successful

thrombendarterectomy normalize exercise capacity and gas exchange?

Harefuah, 2012;151:74-8.

42) Dvir D, Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, Descoutures F,

Moat NE, Testa L, Hengstenberg C, Bekeredjian R, Lefevre T, Guetta V, Nissen H,

Hernández JM, Roy D, Teles R, Segev A, Dumonteil N, Fiorina C, Gotzmann M,

Tchetche D, Abdel-Wahab M, De Marco F, Baumbach A, Laborde JC, Kornowski R.

Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves:

Results from the Global Valve-in-Valve Registry.

Circulation 2012;126: 2335-44 (CARDIAC & CARDIOVASCULAR SYSTEMS 2/128, IF

18.880, cited 365)

43) Segev A, Spiegelstein D, Fefer P, Shinfeld A, Hay I, Raanani E, Guetta V

Trans-catheter aortic valve implantation for non-classical indications.

Isr Med Assoc J 2013;15:399-403 (MEDICINE, GENERAL & INTERNAL 114/154, IF

0.817)

44) Fefer P, Gannot S, Lubetsky A, Martinowitz U, Matetzky S, Guetta V, Segev A


of 93

Percutaneous coronary intervention in patients with haemophilia presenting with

acute coronary syndrome – An interventional dilemma: case series, review of the

literature, and tips for management.

J Thromb Thrombolys, 2013;35:271-8 (HEMATOLOGY 35/79, IF 2.941, cited 8)

45) Beigel R, Brosh S, Goitein O, Guttman E, Novikov I, Segev A, Oieru D, Gerber Y, Konen

E, Hod H, Matetzky S

Prognostic Implications of Non-obstructive Coronary Artery Disease in Patients

Undergoing Coronary Computed Tomography Angiography for Acute Chest Pain.

Am J Cardiol, 2013;111:941-5 (CARDIAC & CARDIOVASCULAR SYSTEMS 49/128, IF 3.171,

cited 0)

46) Beigel R, Matetzky S, Gavrielov-Yusim N, Fefer P, Gottlieb S, Zahger D, Atar S,

Finkelstein A, Roguin A, Goldenberg I, Kornowski R, Segev A

Predictors of high-risk angiographic findings in patients with non ST-elevation acute

coronary syndrome

Catheter Cardiovasc Interv, 2014;83:677-83 (CARDIAC & CARDIOVASCULAR SYSTEMS

60/128, IF 2.602, cited 8)

47) Beigel R, Fefer P, Rosenberg N, Novikov I, Elian D, Fink N, Segev A, Guetta V, Hod

H, Matetzky S.

Anti-platelet effect of thienopyridine (clopidogrel or prasugrel) pre-treatment in

patients undergoing primary percutaneous intervention for ST-elevation myocardial

infarction.

Am J Cardiol, 2013;112:1551-6 (CARDIAC & CARDIOVASCULAR SYSTEMS 49/128, IF

3.171, cited 16)

48) Erez A, Segev A, Medvedofsky D, Fefer P, Raanani E, Goldenberg I, Guetta V.

Factors affecting survival in men versus women following trans-catheter aortic valve

implantation.


of 93


3.171, cited 20)

49) Moriel M, Matetzky S, Segev A, Kornowski R, Danenberg H, Bubyr L, Goldenberg

I, Tzivoni D, Gottlieb S.

Thrombus aspiration in patients with ST-elevation myocardial infraction undergoing

primary percutaneous coronary intervention - Insights from the Acute Coronary

Syndrome Israeli Survey 2010.


3.171, cited 0)

50) Rozen G, Fefer P, Shinfeld A, Sternik L, Guetta V, Malachy A, Levin S, Feinberg M,

Raanani E, Segev A.

The changing characteristics of surgical aortic valve replacement for severe aortic

stenosis in the transcatheter aortic valve implantation era.

J Cardiovasc Med, 2015;16:261-6 (CARDIAC & CARDIOVASCULAR SYSTEMS 87/128, IF

1.670, cited 0)

51) Asman A, Chouraqui P, Marcu-Malina V, Matetzky S, Segev A, Fefer P, Agranat O,

Koltakov A, Hod H, Livneh A, Bank I.

Acute coronary syndromes are associated with a reduction of VLA-1+ peripheral blood

T cells and their enrichment in coronary artery plaque aspirates.

Immunobiology, 2014;219:302-7 (IMMUNOLOGY 88/179, IF 2.873)

52) Fefer P, Gannot S, Kochkina K, Maor E, Matetzky S, Raanani E, Guetta V, Segev A.

Impact of coronary chronic total occlusions on long-term mortality in patients

undergoing coronary artery bypass grafting.

Interact Cardiovasc Thorac Surg, 2014;18:713-6 (CARDIAC & CARDIOVASCULAR

SYSTEMS 81/12, IF 1.756, cited 15)

53) Fefer P, Matetzky S, Gannot S, Gottlieb S, Meerkin D, Gavrielov-Yusim N, Zahger

D, Goldenberg I, Segev A.




of 93

Predictors and outcomes associated with radial versus femoral access for intervention

in patients with acute coronary syndrome: results from the Acute Coronary Syndrome

Israeli Survey (ACSIS) 2010.

J Invasive Cardiol, 2014;26:398-402 (CARDIAC & CARDIOVASCULAR SYSTEMS 93/128,

IF 1.537, cited 0)

54) Medvedofsky D, Klempfner R, Fefer P, Chernomordik F, Hamdan A, Hay I,

Goldenberg I, Raanani E, Guetta V, Segev A.

The significance of pulmonary arterial hypertension pre- and post-transfemoral aortic

valve implantation for severe aortic stenosis.

J Cardiology, 2015;65:337-42 (CARDIAC & CARDIOVASCULAR SYSTEMS 53/128, IF

2.918, cited 9)

55) Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, Schaefer U, Rodés-

Cabau J, Treede H, Piazza N, Hildick-Smith D, Himbert D, Walther T, Hengstenberg C,

Nissen H, Bekeredjian R, Presbitero P, Ferrari E, Segev A, de Weger A, Windecker S,

Moat NE, Barbanti M, Napodano M, Wilbring M, Cerillo AG, Brecker S, Tchetche D,

Lefèvre T, Latib A, De Marco F, Fiorina C, Petronio AS, Teles RC, Testa L, Laborde JC,

Leon MB, Kornowski R. On behalf of the Valve-in-Valve International Data (VIVID)

Registry investigators.

Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical Valves.

JAMA, 2014;312:162-70 (MEDICINE, GENERAL & INTERNAL 3/154, IF 47.661, cited

355)

56) Gannot S, Fefer P, Kopel E, Kuchkina K, Beigel R, Matetzky S, Elian D, Nahum E,

Raanani E, Guetta V, Goldenberg I, Segev A.

her SYNTAX score is not predictive of late mortality in "real-world" patients with

multivessel coronary artery disease undergoing coronary artery bypass grafting.

Isr Med Assoc J, 2014;16:764-7 (MEDICINE, GENERAL & INTERNAL 114/154, IF 0.817)


of 93

Publications since last promotion

57) Maor E, Grossman Y, Balmor RG, Segel M, Fefer P, Ben-Zekry S, Buber J, DiSegni E,

Guetta V, Ben-Dov I, Segev A.

Exercise hemodynamics may enhance the diagnosis of diastolic dysfunction among

patients with pulmonary hypertension.

Eur J Heart Fail, 2015;17:151-8 (CARDIAC & CARDIOVASCULAR SYSTEMS 9/138, IF

11.627 – Q1, cited 20)

58) Sabbag A, Matetzky S, Gottlieb S, Fefer P, Kohanov O, Atar S, Zahger D, Porter A,

Koifman B, Goldenberg I, Segev A.

Recent temporal trends in the presentation, management, and outcome of women

hospitalized with acute coronary syndromes.

Am J Med, 2015;128:380-8 (MEDICINE, GENERAL & INTERNAL 23/165, IF 4.529 – Q1,

cited 14)

59) Hamdan A, Wellnhofer E, Konen E, Kelle S, Goitein O, Andrada B, Raanani E, Segev

A, Barbash I, Klempfner R, Goldenberg I, Guetta V.

Coronary CT angiography for the detection of coronary artery stenosis in patients

referred for transcatheter aortic valve replacement.

J Cardiovasc Comput Tomogr, 2015;9:31-41 (CARDIAC & CARDIOVASCULAR SYSTEMS

50/128, IF 3.095, cited 8)

60) Orvin K, Gottlieb S, Goldenberg I, Matetzky S, Golovchiner G, Kuznietz J, Bubyr L,

Battler A, Kornowski R, Segev A, Strasberg B, Haim M.

Outcome of contemporary acute myocardial infarction patients complicated by

ventricular tachycardia and ventricular fibrillation.

Europace, 2016;18:219-26 (CARDIAC & CARDIOVASCULAR SYSTEMS 25/128, IF 5.231,

cited 10)

61) Petroni T, Zaman A, Georges JL, Hammoudi N, Berman E, Segev A, Juliard JM,

Barthelemy O, Silvain J, Choussat R, Le Feuvre C, Helft G.


of 93

Primary percutaneous coronary intervention for ST elevation myocardial infarction in

nanogenarians: a multicentre study.

Am J Geriatr Soc, 2015;63:384-6 (GERIATRIC & GERONTOLOGY 9/53, IF 4.155)

62) Sabbag A, Guetta V, Amit U, Fefer P, Matetzky S, Gottlieb S, Meisel S, Iakobishvili

Z, Blatt A, Goldenberg I, Segev A.

Temporal trends and outcomes associated with major bleeding events in acute

coronary syndromes. A decade long perspective from the Acute Coronary Syndrome

Israeli Survey 2000-2010.

Cardiology, 2015;132:163-72 (CARDIAC & CARDIOVASCULAR SYSTEMS 93/138, IF

1.791 – Q3)

63) Fink N, Segev A, Barbash I, Bogdan A, Hamdan A, Maor E, Hay I, Spiegelstein D,

Guetta V, Fefer P.

Corticosteroid therapy is associated with more vascular complications in patients

undergoing Trans-femoral Aortic Valve Implantation

Catheter Cardiovasc Interv, 2016;87:341-6. (CARDIAC & CARDIOVASCULAR SYSTEMS

60/128, IF 2.602, cited 0)

64) Bogdan A, Barbash I, Segev A, Fefer P, Bogdan SN, Asher E, Fink N, Hamdan A,

Spiegelstein D, Raanani E, Guetta V.

Albumin correlates with all-cause mortality in elderly patients undergoing trans-

catheter aortic valve implantation

Eurointervention, 2016;12:1057-64 (CARDIAC & CARDIOVASCULAR SYSTEMS 37/128,

IF 4.417, cited )

65) Buber J, Laish-Farkash A, Koren N, Fefer P, Segev A, Doolman R, Hod H, Matetzky

S.

Cardiac troponin elevation pattern in patients undergoing primary percutaneous

coronary intervention for ST-segment elevation myocardial infarction:

Characterization and relationship with cardiovascular events during hospitalization.


of 93

Cor Art Dis, 2015;26:503-9 (CARDIAC & CARDIOVASCULAR SYSTEMS 85/128, IF 1.705,

cited)

66) Hamdan A, Guetta V, Klempfner R, Konen E, Raanani E, Glikson M, Goitein O, Segev

A, Barbash I, Fefer P, Spiegelstein D, Goldenberg I, Schwammenthal E.

Inverse relationship between membranous septal length and the risk of

atrioventricular block in patients undergoing transcatheter aortic valve implantation.

JACC Cardiovasc Interven, 2015;8:1218-28 (CARDIAC & CARDIOVASCULAR SYSTEMS

9/128, IF 9.881, cited 28)

67) Koifman E*, Segev A*, Fefer P, Barbash I, Sabbag A, Medvedofsky D, Spiegelstein

D, Hamdan A, Hay I, Raanani E, Goldenberg I, Guetta V.

Comparison of acute kidney injury classifications in patients undergoing trans-

catheter aortic valve implantation: Predictors and long-term outcomes.

*First 2 authors contributed equally

Catheter Cardiovasc Interv, 2016;87:523-31 (CARDIAC & CARDIOVASCULAR SYSTEMS

85/138, IF 2.044 – Q3, cited 13)

68) Barbash IM, Barbanti M, Webb J, Molina-Martin De Nicolas J, Abramowitz Y, Latib

A, Nguyen C, Deuschl F, Segev A, Sideris K, Santos M, Della Rosa F, Tamburino C,

Jilaihawi H, Miyazaki T, Himbert D, Schofer N, Guetta V, Bleiziffer S, Tchetche D, Immè

S, Makkar R, Vahanian A, Treede H, Lange R, Colombo A, Dvir D.

Comparison of vascular closure devices for access site closure after transfemoral

aortic valve replacement: The ClOsure devices iN TRansfemoral aOrtic vaLve

replacement (CONTROL) multi-center study

Eur Heart J, 2015;36:3370-9 (CARDIAC & CARDIOVASCULAR SYSTEMS 2/138, IF

23.425, cited 42)

69) Berkovitch A, Segev A, Barbash I, Grossman Y, Maor E, Erez A, Regev E, Fink N,

Mazin I, Hamdan A, Goldenberg I, Hay I, Spiegelstien D, Guetta V, Fefer P.

Clinical impact of diabetes mellitus in patients undergoing transcatheter aortic valve

implantation: an historical prospective study


of 93

Cardiovasc Diabetol, 2015;14:131 (CARDIAC & CARDIOVASCULAR SYSTEMS 24/128,

IF 5.235, cited 11)

70) Barbash IM, Finkelstein A, Barsheshet A, Segev A, Halkin A, Assali A, Ben Gal Y,

Vaknin Assa H, Fefer P, Sagie A, Guetta V, Kornowski R,

Outcomes of patients with estimated low and intermediate risk undergoing

transcatheter aortic valve implantation: Results from a Multi-Center Israeli TAVI

Registry


3.171, cited 19)

71) Nachum ER, Raanani E, Segev A, Guetta V, Hay I, Shinfeld A, Fefer P, Hamdan A,

Barbash I, Shalabi A, Spiegelstein D.

Transapical transcatheter valve-in-valve implantation for failed mitral valve

bioprosthesis

Isr Med Assoc J, 2016;18:13-7 (MEDICINE, GENERAL & INTERNAL 114/154, IF 0.807)

72) Gottlieb S, Kolker S, Shlomo N, Matetzky S, Leitersdorf E, Segev A, Goldenberg I,

Tzivoni D, Weisz G, Moriel M.

Association between statin treatment and LDL-cholesterol levels on the rate of ST-

elevation myocardial infarction among patients with acute coronary syndromes: ACS

Israeli Survey (ACSIS) 2002-2010

Int J Cardiol, 2016;210:133-8 (CARDIAC & CARDIOVASCULAR SYSTEMS 41/128, IF

4.034, cited )

73) Goitein O, Di Segni E, Eshet Y, Guetta V, Segev A, Nahum E, Raanani E, Konen E,

Hamdan A.

Non-Valvular Findings before Trans-Catheter Aortic Valve Implantation and their

Impact on the Procedure.

Isr Med Assoc J. 2015;17:764-7 (MEDICINE, GENERAL & INTERNAL 1143/154, IF 0.807)

74) Leibundgut G, Lee JH, Strauss BH, Segev A, Tsimikas S.

http://www.ncbi.nlm.nih.gov/pubmed/?term=Goitein%20O%5BAuthor%5D&cauthor=true&cauthor_uid=26897979

http://www.ncbi.nlm.nih.gov/pubmed/?term=Di%20Segni%20E%5BAuthor%5D&cauthor=true&cauthor_uid=26897979

http://www.ncbi.nlm.nih.gov/pubmed/?term=Eshet%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=26897979

http://www.ncbi.nlm.nih.gov/pubmed/?term=Guetta%20V%5BAuthor%5D&cauthor=true&cauthor_uid=26897979

http://www.ncbi.nlm.nih.gov/pubmed/?term=Segev%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26897979

http://www.ncbi.nlm.nih.gov/pubmed/?term=Nahum%20E%5BAuthor%5D&cauthor=true&cauthor_uid=26897979

http://www.ncbi.nlm.nih.gov/pubmed/?term=Raanani%20E%5BAuthor%5D&cauthor=true&cauthor_uid=26897979

http://www.ncbi.nlm.nih.gov/pubmed/?term=Konen%20E%5BAuthor%5D&cauthor=true&cauthor_uid=26897979

http://www.ncbi.nlm.nih.gov/pubmed/?term=Hamdan%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26897979



of 93

Acute and long-term effect of percutaneous coronary intervention on serially-

measured oxidative, inflammatory, and coagulation biomarkers in patients with stable

angina

J Thromb Thrombolysis. 2016;41:569-80 (HEMATOLOGY 35/71, IF 2.620, cited 1)



Primary percutaneous coronary intervention for ST elevation myocardial infarction in

nonagenarians: a multicentre study

Heart. 2016:102:1648-54 (CARDIAC & CARDIOVASCULAR SYSTEMS 22/128, IF 5.420,

cited )

76) Halkin A, Steinvil A, Witberg G, Barsheshet A, Barkagan M, Assali A, Segev A, Fefer

P, Guetta V, Barbash I, Kornowski R, Finkelstein A.

Mortality prediction following transcatheter aortic valve replacement: A quantitative

comparison of risk scores derived from populations treated with either surgical or

percutaneous aortic valve replacement. The Israeli TAVR Registry Risk Model Accuracy

Assessment (IRRMA) study

Int J Cardiol. 2016:215:227-31 (CARDIAC & CARDIOVASCULAR SYSTEMS 41/128, IF

4.034, cited 13)

77) Asher E, Abu-Much A, Goldenberg I, Segev A, Sabbag A, Mazin I, Shlezinger M, Atar

S, Zahger D, Polak A, Beigel R, Matetzky S.

Incidence and clinical features of early stent thrombosis in the era of new P2Y12

inhibitors (PLATIS-2)

Plos One. 2016;11

78) Landes U, Kerner A, Segev A, Danenberg H, Shapira Y, Finkelstein A, Kornowski R.

Transcatheter tricuspid valve-in-valve implantation in patients with tricuspid

bioprosthetic valve degeneration at high surgical risk – a multicenter case series

Isr Med Assoc J. 2017;19:156-159 (MEDICINE, GENERAL & INTERNAL 114/154, IF

0.807)


of 93

79) Koifman E, Beigel R, Herscovici R, Fefer P, Rozenberg N, Sabbag A, Biton Y, Segev

A, Shechter M, Asher E, Matetzky S.

Immediate response to prasugrel loading in patients with ST-elevation myocardial

infarction: Predictors and outcome.

Thromb Res. 2016:144:176-81 (27/79, IF 3.266)

80) Beigel R, Iakobishvili Z, Shlomo N, Segev A, Wintrob G, Zahger D, Atar S, Alcalai R,

Aronson D, Gottlieb S, Goldenberg I, Asher E, Matetzky S.

Real world use of the novel P2Y12 inhibitors in patients with acute coronary syndrome

– A treatment paradox

Cardiology, 2017:136:21-8 (CARDIAC & CARDIOVASCULAR SYSTEMS 69/125, IF 2.044,

cited 8)

81) Landes U, Barsheshet A, Finkelstein A, Guetta V, Assali A, Halkin A, Vaknin-Assa H,

Segev A, Bental T, Ben-Shoshan J, Barbash IM, Kornowski R.

Temporal trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014:

Patient characteristics, Procedural issues and Clinical Outcome

Clin Cardiol, 2017;40:82-8 (CARDIAC & CARDIOVASCULAR SYSTEMS /125, IF , cited

12)

82) Fink N, Segev A, Kornowski R, Finkelstein A, Assali A, Rozenbaum Z, Vaknin-Assa

H, Halkin A, Fefer P, Ben-Shoshan J, Regev E, Konigstein M, Orvin K, Guetta V, Barbash

I.

Balloon dilatation and outcome among patients undergoing trans-femoral aortic valve

replacement.

Int J Cardiol, 2017;230:537-40 (CARDIAC & CARDIOVASCULAR SYSTEMS 11/125, IF

6.175, cited )

83) Hamdan A, Barbash I, Schwammenthal E, Segev A, Kornowski R, Assali A, Shaviv E,

Fefer P, Goitein O, Konen E, Guetta V




of 93

Gender Differences in Aortic Root Dimensions in Patients Undergoing Transcatheter

Aortic Valve Implantation: A Computer-Tomographic Study

J Cardiovasc Comput Tomogr, 2015;9:31-41 (CARDIAC & CARDIOVASCULAR SYSTEMS

25/125, IF 4.506)

84) Chewing versus swallowing ticagrelor to accelerate platelet inhibition in acute

coronary syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in

Sheba) Study Group.

Asher E, Frydman S, Katz M, Regev E, Sabbag A, Mazin I, Abu-Much A, Kukuy A, Mazo

A, Erez A, Berkovitch A, Narodistky M, Barbash I, Segev A, Beigel R, Matetzky S.

Thromb Haemost. 2017:in-press (HEMATOLOGY 6/68, IF 5.760, cited)

85) Kornowski R, Roguin A, Danenberg H, Vaknin-Assa H, Abergel E, Rozenbaum E,

Guetta V, Landes U, Jabara R, Merdler A, Segev A, Mosseri M, Assali A

BIOFLOW-III satellite – One year clinical outcomes of diabetic patients treated with a

biodegradable polymer sirolimus-eluting stent and comprehensive medical

surveillance

Cardiovasc Revasc Med. 2017;18:338-43 (CARDIAC & CARDIOVASCULAR SYSTEMS

not listed)

86) Witberg G, Regev E, Chen S, Assali A, Barbash I, Planer D, Vaknin-Assa H, Guetta V,

Vukasinovic V, Orvin K, Danenberg H, Segev A, Kornowski R.

The prognostic effects of coronary disease severity and completeness of

revascularization on mortality in patients undergoing transcatheter aortic valve

replacement.

JACC Cardiovasc Interv. 2017;10:1428-35 (CARDIAC & CARDIOVASCULAR SYSTEMS

9/128, IF 9.81)

87) Sabbag A, Matetzky S, Iakobishvili Z, Porter A, Moriel M, Zwas D, Fefer P, Asher E,

Beigel R, Gottlieb S, Goldenberg I, Segev A

Sex differences affecting the management anf 5-year outcome of young patients

(<55y) with acute coronary syndromes

https://www.ncbi.nlm.nih.gov/pubmed/28150850




of 93

Am J Med. 2017;130:1324 (MEDICINE, GENERAL & INTERNAL 23/165, IF 4.529 – Q1,

cited 8)

88) Witberg G, Finkelstein A, Barbash I, Assali A, Shapira Y, Segev A, Halkin A, Fefer P,

Ben-Shoshan J, Konigstein M, Sagie A, Guetta V, Kornowski R, Barsheshet A.

Prognostic significance of aortic valve gradient in patients with severe aortic stenosis

undergoing transcatheter aortic valve replacement.

Catheter Cardiovasc Interven. 2017;90:1175-82 (CARDIAC & CARDIOVASCULAR

SYSTEMS 60/128, IF 2.620)

89) Fefer P, Beigel R, Atar S, Aronson D, Pollak A, Zahger D, Asher E, Iakobishvili Z,

Shlomo N, Alcalai R, Einhorn M, Segev A, Goldenberg I, Matetzky S.

Outcomes of patients presenting with clinical indices of spontaneous reperfusion in

ST-elevation acute coronary syndrome undergoing deferred angiography

J Am Heart Associat. 2017:6 (CARDIAC & CARDIOVASCULAR SYSTEMS 36/128, IF

4.450)

90) Grossman Y, Barbash IM, Fefer P, Bogdan A, Goldenberg I, Berkovitch A, Erez A,

Regev E, Fink N, Asher E, Hay I, Spigelstein D, Orlov B, Nacum E, Raanani, Guetta V,

Segev A.

Addition of albumin to traditional risk score improves prediction of mortlaity in

individuals undergoing transcatheter aortic valve replacement

J Am Geriat Soc. 2017;65:2412-7 (GERIATRIC & GERONTOLOGY 12/138, IF 4.180 – Q1)

91) Regev E, Finkelstein A, Assali A, Barbash I, Fefer P, Ben-Shoshan J, Orvin K,

Konigstein M, Guetta V, Kornowski R, Segev A.

Comparison of outcome of transcatheter aortic valve implantation for severe aortic

stenosis in 3 age groups (≤70; 71-80 and ≥81 Years).

Am J Cardiol. 2017;120:1607-11 (CARDIAC & CARDIOVASCULAR SYSTEMS 63/138, IF

2.570 – Q2)


of 93

92) Levi Y, Frimerman A, Shotan A, Shochat M, Blondheim DS, Segev A, Goldenerg I,

Kazatsker M, Vasilenko L, Shlomo N, Meisel SR.

Primary percutaneous coronary intervention versus in-hospital thrombolysis as

reperfusion therapy in early-arriving low-risk STEMI patients.

Isr Med Assoc J. 2017;16:345-350. (MEDICINE, GENERAL & INTERNAL 129/165, IF

0.860)

93) Mazin I, Matetzky S, Shemer L, Fourey D, Fefer P, Segev A, Abu-Much A, Beigel R,

Asher E.

The “burden” of malignancy in a tertiary hospital intensive cardiovascular care unit.

Cardiology. 2017;138:195-9. (CARDIAC & CARDIOVASCULAR SYSTEMS 103/136, IF

1.561)

94) Asher E, Tal S, Mazin I, Abu-Much A, Sabbag A, Katz M, Regev E, Chernomordik F,

Guetta V, Segev A, Elian D, Barbash I, Fefer P, Narodistky M, Beigel R, Matetzky S.

Effect of chewing vs. swallowing ticagrelor om platelet inhibition in patients with ST-

elevation myocardial infraction: A randomized clinical trial.

JAMA Cardiol. 2017;2:1380-4. (CARDIAC & CARDIOVASCULAR SYSTEMS 7/136, IF

11.866)

95) Koifan E, Beigel R, Iakobishvili Z, Shlomo N, Biton Y, Asher E, Atar S, Gottlieb S,

Zahger D, Segev A, Goldenberg I, Strugo R, Matetzky S.

Impact of mobile intensive care unit use on total ischemic time and clinical outcomes

in ST-elevation muocardial infarction patients – real-world data from the Cute

Coronary Syndrome Israeli Survey.

Eur Heart J Acute Cardiovasc Care. 2018;7:497-503 (CARDIAC & CARDIOVASCULAR

SYSTEMS 47/136 IF 3.734)

96) Berkovitch A, Guetta V, Barbash IM, Fink N, Regev E, Maor E, Vered Y, Grossman

Y, Younis A, Kuperstein R, Feinberg M, Asher E, Segev A, Fefer P.

Favorable short and long-term outcomes among patients with prior history of

malignancy undergoing transcatheter aortic valve implantation.




of 93

J Invasive Cardiol 2018;30:105-9 (CARDIAC & CARDIOVASCULAR SYSTEMS 112/136,

IF 1.363)

97) Ram E, Goldenberg I, Kassif Y, Segev A, Lavee J, Shlomo N, Raanani E.

Comparison of patients with multivessel disease treated at centers with and without

on-site cardiac surgery.

J Thorac Cardiovasc Surg 2018;155:865-73. (CARDIAC & CARDIOVASCULAR SYSTEMS

24/136, IF 5.261)

98) Ram E, Goldenberg I, Kassif Y, Segev A, Lavee J, Einhorn-Cohen M, Raanani E.

Real-life characteristics and outcomes of patients who undergo percutaneous

coronary intervention versus coronary artery bypass grafting for left main coronary

artery disease: data from the prospective Multi-vessel Coronary Artery Disease

(MULTICAD) Israeli Registry.

Eur J Cardiothorac Surg 2018;54:717-23 (CARDIAC & CARDIOVASCULAR SYSTEMS

46/136, IF 3.847)

99) Graham-Cummiskey A, Segev A*, Segel M, Buber J, Guetta V, Barbash IM, Elian D,

Asher E, Vaturi O, Fefer P. *Equal contribution

Exercise hemodynamics for the diagnosis of diastolic dysfunction in dyspneic patients

with systemic sclerosis.

Isr Med Assoc J 2018;20:245-9. (MEDICINE, GENERAL & INTERNAL 129/165, IF 0.860

– Q4)

100) Fefer P, Bogdan A, Grossman Y, Berkovitch A, Brodov Y, Kuperstein R, Segev A,

Guetta V, Barbash I.

Impact of Rapid Ventricular Pacing on Outcome After Trans-Catheter Aortic Valve

Replacement.

J Am Heart Assoc. 2018;9 (CARDIAC & CARDIOVASCULAR SYSTEMS 34/136, IF 4.66)

101) Grossman Y, Silverberg D, Berkovitch A, Chernomordik F, Younis A, Asher E,

Barbash I, Halak M, Guetta V, Segev A, Fefer P.










of 93

Long-term outcomes of ilio-femoral artery stents following trans-femoral aortic valve

replacement.

J Vasc Interven Radiol. 2018;29:1733-40 (RADIOLOGY 40/239, IF 2.758)

102) Fink N, Nikolsky E, Assali A, Shapira O, Kassif Y, Barac Y, Finkelstein A, Eitan A,

Danenberg H, Zahger D, Sahar G, Atar S, Raanani E, Bolotin G, Goldenberg I, Segev A.

Revascularization strategies and survival in patients with multi-vessel coronary artery

disease.

Ann Thorac Surg. 2019;107:106-11 (CARDIAC & CARDIOVASCULAR SYSTEMS 49/138

– Q2, IF 3.639; SURGERY 34/210 – Q1)

103) Finkelstein A, Steinvil A, Rozenbaum Z, Halkin A, Banai S, Barbash I, Guetta V,

Segev A, Danenberg H, Orvin K, Vaknin Assa H, Assali A, Kornowski R.

Efficacy and safety of new generation transcatheter aortic valves: Insights from the

Israeli Transcatheter Aortic Valve Replacement registry.

Clin Res Cardiol. 2018;4:430-7 (CARDIAC & CARDIOVASCULAR SYSTEMS 32/136, IF

4.907)

104) Biton D, Grossman Y, Finkelstein A, Assali A, Halkin A, Brodov Y, Fefer P, Barbash

IM, Goitein O, Landes U, Arbel Y, Guetta V, Koronowski R, Segev A.

Transcatheter aortic valve replacement in the presence of mitral prosthesis or ring.

Structural Heart. 2019;2:134-7 (CARDIAC & CARDIOVASCULAR SYSTEMS not listed)

105) Finkelstein A, Rozenbaum Z, Zhitomirsky S, Halkin A, Banai S, Bazan S, Barbash I,

Segev A, Guetta V, Danenberg H, Planner D, Orvin K, Assa HV, Assali A, Kornowski R,

Steinvil A.

Safety outcomes of new versus old generation transcatheter aortic valves.

Catheter Cardiovasc Interv. 2019;94:E44-53 (CARDIAC & CARDIOVASCULAR SYSTEMS

64/136, IF 2.551)

106) Finkelstein A, Rozenbaum Z, Halkin A, Banai S, Barbash I, Segev A, Guetta V,

Danenberg H, Planner D, Orvin K, Vaknin Assa H, Assali A, Kornowski R, Steinvil A.



of 93

Outcomes of transcatheter aortic valve implantation in patients with low versus

intermediate to high surgical risk.

Am J Cardiol 2019;123:644-9 (CARDIAC & CARDIOVASCULAR SYSTEMS 59/136, IF

2.843)

107) Itzhaki Ben Zadok O, Kornowski R, Finkelstein A, Barbash I, Danenberg H, Segev

A, Guetta V, Halkin A, Planer D, Vaknin H, Assali A, Barsheshet A, Orvin K.

Temporal trends in gender-related differences and outcomes in patients who

underwent transcatheter aortic valve implantation (from the Israeli TAVI multi-center

registry).


2.843)

108) Younis A, Orvin K, Nof E, Barabash IM, Segev A, Berkovitch A, Guetta V, Assali A,

Kornowski R, Beinart R.

The effect of periprocedural beta blocker withdrawal on arrhythmic risk following

transcatheter aortic valve replacement.

Catheter Cardiovasc Interv. 2019;93:1361-6 (CARDIAC & CARDIOVASCULAR SYSTEMS

64/136, IF 2.551)

109) Brodov Y, Konen E, DiSegni M, Samooha D, Barbash I, Regev E, Raanani E, Guetta

V, Segev A, Fefer P, Glikson M, Goitein O.

Mitral annulus calcium score - an independent predictor of new conduction system

abnormalities in patients after transcatheter aortic valve implantation.

Circ Cardiovasc Imaging 2019; (CARDIAC & CARDIOVASCULAR SYSTEMS 21/136, IF

5.813)

110) Ram E, Goldenberg I, Sternik L, Peled Y, Segev A, Kogan A, Vorobeichik Pechersky

D, Shlomo N, Raanani E.

Real-world referral pattern and outcomes of diabetic patients who undergo

revascularization: data from the prospective Multi-vessel Coronary Artery Disease

(MULTICAD) Israeli Registry.



https://www.ncbi.nlm.nih.gov/pubmed/?term=Ram%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30805588

https://www.ncbi.nlm.nih.gov/pubmed/?term=Goldenberg%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30805588

https://www.ncbi.nlm.nih.gov/pubmed/?term=Sternik%20L%5BAuthor%5D&cauthor=true&cauthor_uid=30805588

https://www.ncbi.nlm.nih.gov/pubmed/?term=Peled%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=30805588

https://www.ncbi.nlm.nih.gov/pubmed/?term=Segev%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30805588

https://www.ncbi.nlm.nih.gov/pubmed/?term=Kogan%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30805588

https://www.ncbi.nlm.nih.gov/pubmed/?term=Vorobeichik%20Pechersky%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30805588

https://www.ncbi.nlm.nih.gov/pubmed/?term=Vorobeichik%20Pechersky%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30805588

https://www.ncbi.nlm.nih.gov/pubmed/?term=Shlomo%20N%5BAuthor%5D&cauthor=true&cauthor_uid=30805588

https://www.ncbi.nlm.nih.gov/pubmed/?term=Raanani%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30805588


of 93

Eur J Cardiothorac Surg 2019 (CARDIAC & CARDIOVASCULAR SYSTEMS 46/136, IF

3.847)

111) Baldetti L, Giannini F, Van Mieghem N, El Faquir N, Tchétché D, De Biase C,

Petronio AS, Giannini C, Tarantini G, Fraccaro C, Finkelstein A, Segev A, Barbash I,

Bruschi G, Tamburino C, Barbanti M, Lim S, Kuntjoro I, Abdel-Wahab M, Colombo A,

Latib A.

Outcome of patients undergoing transcatheter implantation of aortic valve with

previous mitral valve prosthesis (OPTIMAL) study.

Can J Cardiol 2019;35:866-874 (CARDIAC & CARDIOVASCULAR SYSTEMS 23/136, IF

5.592)

112) Orvin K, Ben Zekry S, Morelli O, Barbash I, Segev A, Danenberg H, Assali A, Guetta

V, Vaknin Assa H, Zeniou V, Lotan C, Sagie A, Gilon D, Feinberg M, Shapira Y, Kornowski

R

Long-term functional and structural durability of bioprosthetic valves placed in the

aortic valve position via percutaneous route in Israel.


2.843)

113) Rozenbaum Z, Finkelstein A, Zhitomiesky S, Topilsky Y, Halkin A, Banai S, Bazan S,

Barbash I, Segev A, Guetta V, Danenberg H, Planner D, Orvin K, Vaknin Assa H, Assali

A, Kornowski R, Steinvil A.

Impact of pre-procedural left ventricle hypertrophy and geometrical patterns on

mortality following TAVR.

Am Heart J 2019;220:184-91 (CARDIAC & CARDIOVASCULAR SYSTEMS 41/136, IF

4.023)

114) Neeman BB, Maor E, Barbash IM, Hay I, Vatury O, Ben Zekry S, Segev A, Feinberg

M, Guetta V, Fefer P.

Outcome of patients turned down from percutaneous mitral valve repair.

J Invasive Cardiol, 2019;in-press (CARDIAC & CARDIOVASCULAR SYSTEMS /136, IF )


of 93

115) Barbash IM, Kornowski R, Erlebach M, Berkovitch A, Assali A, Guetta V, Vaknin

Assa H, Lange R, Segev A, Ruge H.

Percutaneous nitinol-based vascular closure device for large bore arterial access

hemostasis: Results of a prospective multicenter study

Catheter Cardiovasc Interven 2020;in-press (CARDIAC & CARDIOVASCULAR SYSTEMS

64/136, IF 2.551)

116) Berkovitch A, Barbash IM, Finkelstein A, Assali A, Danenberg H, Fefer P, Maor E,

Zhitomirsky S, Orvin K, Steinvil A, Barsheshet A, Halkin A, Guetta V, Kornowski R, Segev

A

Validation of the cardiac damage classification and additional effects of albumin levels

in a large cohort of patients undergoing transcatheter aortic valve replacement.

Int J Cardiol 2020;in-press (CARDIAC & CARDIOVASCULAR SYSTEMS 55/138, IF 3.229

– Q2)

117) Zusman O, Landes U, Barbash IM, Finkelstein A, Danenberg H, Segev A, Guetta V,

Orvin K, Assali A, Barsheshet A, Kornowski R.

Predicting the Risk of Late Futile Outcome after Transcatheter Aortic Valve

Replacement.

Catheter Cardiovasc Interven 2020;in-press (CARDIAC & CARDIOVASCULAR SYSTEMS

64/136, IF 2.551)

118) Ram E, Raanani E, Klempfner R, Peled Y, Sternik L, Segev A.

Mid-term outcomes of patients with multi-vessel disease treated at centers with and

without on-site cardiac surgery service.

J Thorac Cardiovasc Surg 2020; in-press (CARDIAC & CARDIOVASCULAR SYSTEMS

33/138, IF 4.451 - Q1; SURGERY 17/210 - Q1)

119) Dai H, Abu Much A, Maor E, Segev A, Beinart R, Adawi S, Zhang Q, Bragazzi NL,

Wu J.


of 93

Global, regional, and national prevalence, incidence, mortality, and risk factors for

atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017.

Eur Heart J Qual Care Clin Outcomes 2020; in-press

120) Fardman A, Oren D, Berkovitch A, Segev A, Levy Y, Beigel R, Matetzky S.

Post Covid-19 acute myocardial infarction rebound.

Can J Cardiol 2020;in-press (CARDIAC & CARDIOVASCULAR SYSTEMS 27/138, IF 5.000

- Q1)

121) Witberg G, Segev A, Barac YD, Raanani E, Assali A, Finkelstein A, Roguin A, Sahar

G, Vaknin-Assa H, Bolotin G, Eitan A, Klempfner R, Goldenberg I, Kornowski R.

Heart team/guidelines discordance is associated with increased mortality - Data from

a national survey of revascularization in complex coronary artery disease patients.

Circulation Cardiovasc Interven 2020;in-press

122) Ram E, Lavee J, Sternik L, Segev A, Peled Y.

Relation of Age to Risk of Major Rejections, Allograft Vasculopathy, and Long-Term

Mortality in a Contemporary Cohort of Patients Undergoing Heart Transplantation.

Isr Med Assoc J 2020;22:486-90. 123) Asher E, Abu Much A, Bragazzi NL, Younis A, Younis A, Masalha E, Goldkorn R,

Mazin I, Fefer P, Barbash IM, Segev A, Maor E, Beigel R, Matetzky S.

CHADS2 and CHADS2VASc Scores as Predictors of Platelet Reactivity in Acute Coronary

Syndrome: For the PLATIS (Platelets and Thrombosis in Sheba) Study Group.

J Cardiol 2020;in-press

124) Ram E, Beckerman P, Segev A, Shlomo N, Atias-Lazar A, Sternik L, Raanani E.

The predictive value of creatinine clearance for mortality in patients undergoing

revascularization.

B.1. ORIGINAL ARTICLES – SUBMITTED/UNDER REVISION:


of 93

Fardman A, Zahger D, Orvin K, Oren D, Kofman N, Mohsen J, Tsafrir O, Asher E,

Rubinshtein R, Jamal J, Efraim R, Halabi M, Shacham Y, Fortis LH, Ovdat T, Klempfner

R, Raanani E, Segev A, Beigel R, Matetzky S.

Acute myocardial infarction in Covid-19 era: incidence, clinical characteristics and in-

hospital outcomes: multicenter registry.

Fefer P, Shaham L, Cummiskey G, Barbash I, Buber I, Maor E, Guetta V, Segev A.

The Effect of Exercise on Pulmonary Capillary Wedge Pressure in a Wide Range of

Patients Undergoing Right Heart Catheterization.

Berkovitch A, Finkelstein A, Barbash IM, Fefer P, Maor E, Banai S, Brodov Y, Goitein O,

Aviram G, Halkin A, Guetta V, Steinvil A, Segev A.

Invasive- versus computed tomography-angiography for the evaluation of coronary

artery disease among elderly patients undergoing transcatheter aortic valve

implantation

Valdebenito M, Massalha E, Barbash IM, Maor E, Fefer P, Guetta V, Segev A

Transcatheter Aortic Valve Replacement is effective and safe during the COVID-19

pandemic. Insights from a single, tertiary-care center.

Generational differences in outcomes of self-expandable valves for transcatheter

aortic valve replacement.

Prognostic implication of right ventricular dysfunction and tricuspid regurgitation

following transcatheter aortic valve replacement

B.2. CASE REPORTS – PUBLISHED

1) Segev A, Ben-Chetrit S, Orion Y, Segev F, Bernhheim J, Bernheim J, Mekori YA.

Acute eosinophilic interstitial nephritis and uveitis (TINU Syndrome) associated with

granulomatous hepatitis.


of 93

Clin Nephrology 1999, 51:310-3 (UROLOGY & NEPHROLOGY 54/73, IF 1.288)

2) Segev A, Manor Y, Bernheim J, Mekori YA.

Light chain myeloma presenting as severe obstructive jaundice from hepatic

amyloidosis.

Eur J Haematol 1999, 63:364-365 (HEMATOLOGY 34/67, IF 2.548)

3) Mor A, Segev A, Hershkoviz R, Mekori YA.

Hypereosinophilic syndrome presenting as acute myocardial infarction.

Allergy 2000, 55:899-900 (IMMUNOLOGY 19/137, IF 5.883)

4) Mor A, Segev A, Hershkoviz R, Mekori YA.

Thallium scan and pulmonary carcinoma.

Harefuah 2000, 138:831-833 (Hebrew)

5) Segev A, Hadari R, Zehavi T, Hershkoviz R, Schneider M, Mekori YA.

Lupus-like syndrome with sub-massive hepatic necrosis associated with hepatitis A.

J Gastroenterol Hepatol 2001, 16:112-4 (GASTROENTEROLOGY & HEPATOLOGY

22/74, IF 3.325)

6) Segev F, Segev A, Livne A, Assia EI, Mekori YA.

Bilateral central retinal vein occlusion in a patient with occult colon cancer.

Arch Ophthalmol 2001, 119:1552-3 (OPHTHALMOLOGY 3/59, IF 3.826)

7) Segev A, Strauss BH, Coates J, Freeman MR, Gallo R.

Endocardial cryotherapy as a novel strategy of improving myocardial perfusion in a

patient with severe coronary artery disease.

Catheter Cardiovasc Interv 2003, 60:229-232 (CARDIAC & CARDIOVASCULAR

SYSTEMS 55/124, IF 2.514)


of 93

8) Erez A, Barbash I, Spiegelstein D, Kogan A, Hamdan A, Shinfeld A, Preisman A, Segev

A.

Extrinsic compression of the left main coronary artery by a contained aortic annular

rupture following trans-catheter aortic valve implantation.

Cardiovasc Revasc Med 2015;16:313-6 (CARDIAC & CARDIOVASCULAR SYSTEMS not

listed)

9) Barbash IM, Bogdan A, Fefer P, Spiegelstein D, Raanani E, Beinart R, Guetta V, Segev

A.

How should I treat a left ventricular outflow tract-migrated balloon-expandable

transcatheter heart valve?

EuroIntervention. 2016;11:1442-5

10) Asher E, Guetta V, Segev A.

Neoatherosclerosis in a bare metal stent: A new problem of atherosclerosis.

Isr Med Assoc J 2016:18:306

11) Asher E, Kogan A, Segev A.

Severe upper abdominal pain in a 43-year-old woman.

Heart. 2017;103:1950

12) Abu-Much A, Barbash IM, Guetta V, Segev A, Fefer P, Matetzky S, Nissan N, Maor

E.

Don’t trust the imaging: Necrotic bowel following transcatheter aortic valve

replacement through aortic stent graft.

JACC Case Reports 2020;in-press

B.3. REVIEWS – PUBLISHED:

1) Segev A, Nili N, Strauss BH.

The role of perlecan in arterial injury and angiogenesis.

Cardiovasc Res 2004, 63:603-610. (CARDIAC & CARDIOVASCULAR SYSTEMS 12/124,

IF 5.940, cited 73)




of 93

2) Segev A, Strauss BH.

Novel approaches for the treatment of chronic total coronary occlusions.

J Interven Cardiol, 2004, 17:411-416. (CARDIAC & CARDIOVASCULAR SYSTEMS,

73/124, IF 1.500)

3) Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C,

Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann

FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L,

Valgimigli M, Wijns W, Witkowski A.

Collaborators: Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean

V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P,Knuuti J, Kolh

P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes

PA, Tamargo JL, Tendera M, Torbicki A, Wijns W,Windecker S, Sousa Uva

M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui

F, Bonaros N, De Carlo M,Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai

D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan

AJ,Sanmartin M, Sergeant P, Silber S, Tamargo J, Ten Berg J, Thiele H, van Geuns

RJ, Wagner HO, Wassmann S, Wendler O, Zamorano JL,Weidinger F, Ibrahimov

F, Legrand V, Terzic I, Postadzhiyan A, Skoric B, Georgiou GM, Zelizko M, Junker A, Eha

J, Romppanen H, Bonnet JL,Aladashvili A, Hambrecht R, Becker D, Gudnason T, Segev

A, Bugiardini R, Sakhov O, Mirrakhimov A, Pereira B, Felice H, Trovik T, Dudek

D,Pereira H, Nedeljkovic MA, Hudec M, Cequier A, Erlinge D, Roffi M, Kedev S, Addad

F, Yildirir A, Davies J.

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on

Myocardial Revascularization of the European Society of Cardiology (ESC) and the

European Association for Cardio-Thoracic Surgery (EACTS).

Eur Heart J, 2014;35:2541-619 (CARDIAC & CARDIOVASCULAR SYSTEMS 3/125, IF

14.723 )

4) Finkelstein A, Minha S, Kornowski R, Danenberg H, Banai S, Lotan H, Segev A,

Barbash IM.

http://www.ncbi.nlm.nih.gov/pubmed/?term=Zamorano%20JL

http://www.ncbi.nlm.nih.gov/pubmed/?term=Achenbach%20S

http://www.ncbi.nlm.nih.gov/pubmed/?term=Baumgartner%20H

http://www.ncbi.nlm.nih.gov/pubmed/?term=Bax%20JJ

http://www.ncbi.nlm.nih.gov/pubmed/?term=Bueno%20H

http://www.ncbi.nlm.nih.gov/pubmed/?term=Dean%20V

http://www.ncbi.nlm.nih.gov/pubmed/?term=Dean%20V

http://www.ncbi.nlm.nih.gov/pubmed/?term=Deaton%20C

http://www.ncbi.nlm.nih.gov/pubmed/?term=Erol%20C

http://www.ncbi.nlm.nih.gov/pubmed/?term=Fagard%20R

http://www.ncbi.nlm.nih.gov/pubmed/?term=Ferrari%20R

http://www.ncbi.nlm.nih.gov/pubmed/?term=Hasdai%20D

http://www.ncbi.nlm.nih.gov/pubmed/?term=Hoes%20AW

http://www.ncbi.nlm.nih.gov/pubmed/?term=Kirchhof%20P

http://www.ncbi.nlm.nih.gov/pubmed/?term=Knuuti%20J

http://www.ncbi.nlm.nih.gov/pubmed/?term=Kolh%20P

http://www.ncbi.nlm.nih.gov/pubmed/?term=Kolh%20P

http://www.ncbi.nlm.nih.gov/pubmed/?term=Lancellotti%20P

http://www.ncbi.nlm.nih.gov/pubmed/?term=Linhart%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Nihoyannopoulos%20P

http://www.ncbi.nlm.nih.gov/pubmed/?term=Piepoli%20MF

http://www.ncbi.nlm.nih.gov/pubmed/?term=Ponikowski%20P

http://www.ncbi.nlm.nih.gov/pubmed/?term=Sirnes%20PA

http://www.ncbi.nlm.nih.gov/pubmed/?term=Sirnes%20PA

http://www.ncbi.nlm.nih.gov/pubmed/?term=Tamargo%20JL

http://www.ncbi.nlm.nih.gov/pubmed/?term=Tendera%20M

http://www.ncbi.nlm.nih.gov/pubmed/?term=Torbicki%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Wijns%20W

http://www.ncbi.nlm.nih.gov/pubmed/?term=Windecker%20S

http://www.ncbi.nlm.nih.gov/pubmed/?term=Sousa%20Uva%20M

http://www.ncbi.nlm.nih.gov/pubmed/?term=Sousa%20Uva%20M

http://www.ncbi.nlm.nih.gov/pubmed/?term=Achenbach%20S

http://www.ncbi.nlm.nih.gov/pubmed/?term=Pepper%20J

http://www.ncbi.nlm.nih.gov/pubmed/?term=Anyanwu%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Badimon%20L

http://www.ncbi.nlm.nih.gov/pubmed/?term=Bauersachs%20J

http://www.ncbi.nlm.nih.gov/pubmed/?term=Baumbach%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Beygui%20F

http://www.ncbi.nlm.nih.gov/pubmed/?term=Beygui%20F

http://www.ncbi.nlm.nih.gov/pubmed/?term=Bonaros%20N

http://www.ncbi.nlm.nih.gov/pubmed/?term=De%20Carlo%20M

http://www.ncbi.nlm.nih.gov/pubmed/?term=Deaton%20C

http://www.ncbi.nlm.nih.gov/pubmed/?term=Dobrev%20D

http://www.ncbi.nlm.nih.gov/pubmed/?term=Dunning%20J

http://www.ncbi.nlm.nih.gov/pubmed/?term=Eeckhout%20E

http://www.ncbi.nlm.nih.gov/pubmed/?term=Gielen%20S



http://www.ncbi.nlm.nih.gov/pubmed/?term=Kirchhof%20P

http://www.ncbi.nlm.nih.gov/pubmed/?term=Luckraz%20H

http://www.ncbi.nlm.nih.gov/pubmed/?term=Mahrholdt%20H

http://www.ncbi.nlm.nih.gov/pubmed/?term=Montalescot%20G

http://www.ncbi.nlm.nih.gov/pubmed/?term=Paparella%20D

http://www.ncbi.nlm.nih.gov/pubmed/?term=Rastan%20AJ

http://www.ncbi.nlm.nih.gov/pubmed/?term=Rastan%20AJ

http://www.ncbi.nlm.nih.gov/pubmed/?term=Sanmartin%20M

http://www.ncbi.nlm.nih.gov/pubmed/?term=Sergeant%20P

http://www.ncbi.nlm.nih.gov/pubmed/?term=Silber%20S

http://www.ncbi.nlm.nih.gov/pubmed/?term=Tamargo%20J

http://www.ncbi.nlm.nih.gov/pubmed/?term=Ten%20Berg%20J

http://www.ncbi.nlm.nih.gov/pubmed/?term=Thiele%20H

http://www.ncbi.nlm.nih.gov/pubmed/?term=van%20Geuns%20RJ

http://www.ncbi.nlm.nih.gov/pubmed/?term=van%20Geuns%20RJ

http://www.ncbi.nlm.nih.gov/pubmed/?term=Wagner%20HO

http://www.ncbi.nlm.nih.gov/pubmed/?term=Wassmann%20S

http://www.ncbi.nlm.nih.gov/pubmed/?term=Wendler%20O

http://www.ncbi.nlm.nih.gov/pubmed/?term=Zamorano%20JL

http://www.ncbi.nlm.nih.gov/pubmed/?term=Weidinger%20F

http://www.ncbi.nlm.nih.gov/pubmed/?term=Ibrahimov%20F

http://www.ncbi.nlm.nih.gov/pubmed/?term=Ibrahimov%20F

http://www.ncbi.nlm.nih.gov/pubmed/?term=Legrand%20V

http://www.ncbi.nlm.nih.gov/pubmed/?term=Terzic%20I

http://www.ncbi.nlm.nih.gov/pubmed/?term=Postadzhiyan%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Skoric%20B

http://www.ncbi.nlm.nih.gov/pubmed/?term=Georgiou%20GM

http://www.ncbi.nlm.nih.gov/pubmed/?term=Zelizko%20M

http://www.ncbi.nlm.nih.gov/pubmed/?term=Junker%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Eha%20J

http://www.ncbi.nlm.nih.gov/pubmed/?term=Eha%20J

http://www.ncbi.nlm.nih.gov/pubmed/?term=Romppanen%20H

http://www.ncbi.nlm.nih.gov/pubmed/?term=Bonnet%20JL

http://www.ncbi.nlm.nih.gov/pubmed/?term=Aladashvili%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Hambrecht%20R

http://www.ncbi.nlm.nih.gov/pubmed/?term=Becker%20D

http://www.ncbi.nlm.nih.gov/pubmed/?term=Gudnason%20T

http://www.ncbi.nlm.nih.gov/pubmed/?term=Segev%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Segev%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Bugiardini%20R

http://www.ncbi.nlm.nih.gov/pubmed/?term=Sakhov%20O

http://www.ncbi.nlm.nih.gov/pubmed/?term=Mirrakhimov%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Pereira%20B

http://www.ncbi.nlm.nih.gov/pubmed/?term=Felice%20H

http://www.ncbi.nlm.nih.gov/pubmed/?term=Trovik%20T

http://www.ncbi.nlm.nih.gov/pubmed/?term=Dudek%20D

http://www.ncbi.nlm.nih.gov/pubmed/?term=Dudek%20D

http://www.ncbi.nlm.nih.gov/pubmed/?term=Pereira%20H

http://www.ncbi.nlm.nih.gov/pubmed/?term=Nedeljkovic%20MA

http://www.ncbi.nlm.nih.gov/pubmed/?term=Hudec%20M

http://www.ncbi.nlm.nih.gov/pubmed/?term=Cequier%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Erlinge%20D

http://www.ncbi.nlm.nih.gov/pubmed/?term=Roffi%20M

http://www.ncbi.nlm.nih.gov/pubmed/?term=Kedev%20S

http://www.ncbi.nlm.nih.gov/pubmed/?term=Addad%20F

http://www.ncbi.nlm.nih.gov/pubmed/?term=Addad%20F

http://www.ncbi.nlm.nih.gov/pubmed/?term=Yildirir%20A

http://www.ncbi.nlm.nih.gov/pubmed/?term=Davies%20J





of 93

Israel: coronary and structural heart interventions from 2010 to 2015.

EuroIntervention. 2017;13(Z):Z32-Z36.

C. BOOK CHAPTERS:

1) Segev A, Sierevogel MJ, Pasterkamp G, Strauss BH.

The Role of Matrix Metalloproteinases Inhibitors after Arterial Injury. In: de Scheerder

I, Camenzind E (editors). Local Drug Delivery for Coronary Artery Disease. Established

and Emerging applications. Taylor & Francis, A Martin Dunitz Publishing, London.

2005; chapter 26, pp 229-237

2) Asher E, Segev A

Antithrombotic treatment in patients undergoing transcatheter aortic valve

replacement. In: Topaz O (editor). Cardiovascular Thrombus. Elsevier academic press,

London. 2018; chapter 43, pp 605-614

D1. INVITED PAPERS IN INTERNATIONAL SCIENTIFIC MEETINGS 1. Segev A. Plaque digestion with collagenase: an alternative treatment strategy for

chronic total occlusions. Transcatheter Cardiovascular Therapeutics (TCT),

Washington, DC, USA. Oct 2004.

2. Segev A. Perlecan inducers: a novel approach for drug-eluting stents.

Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA. Oct 2004.

3. Segev A. Interventional ‘digestion’ of chronic total occlusions. GCI – Global

Cardiovascular Interventions, Frankfurt, Germany. Nov 2004

4. Segev A. Chronic Total Occlusions: Exploring the Final Fronteir. Pharmacologic

Dissolution: Collagenase. Transcatheter Cardiovascular Therapeutics (TCT),

Washington, DC, USA. October 2005.

5. Segev A. Technical strategies in CTO revascularization. 1st Israeli Chronic Total

Occlusion Meeting. Jerusalem, Israel. May 2007

6. Segev A. Primary PCI in SVG occlusion. EUROPCR, Barcelona, Spain. May 2007

7. Segev A. FIM Multicenter Randomized Study: The Ovalum CiTop™ Guidewire

System for Recanalization of Peripheral CTOs. EuroPCR, Barcelona, Spain. May

2008



of 93

8. Segev A. FIM Study: The Ovalum CiTop™ Expander™ Guidewire for Recanalization

of Coronary CTOs. EuroPCR, May 2009, Barcelona, Spain

9. Segev A. The role of thrombus aspiration in patients undergoing primary PCI.

Montreal Interventional Cardiology Meeting, Montreal, Canada, June 2009

10. Segev A. The Ovalum CiTop™ Guidewire for recanalization of chronic total

occlusion. Transcatheter Cardiovascular Therapeutics (TCT), San Francisco, CA,

USA. September 2009

11. Segev A. Therapeutic options for late drug-eluting stents failure. 6th International

Meeting on Intensive Cardiac Care, Tel-Aviv, Israel, October 2009

12. Segev A. Primary PCI in patients with multi-vessel disease Beyond the culprit

lesion? EuroPCR, May 2010, Paris, France.

13. Segev A. A Perlecan-Inducing Compound Significantly Inhibits Smooth Muscle Cell

Function and In-stent Intimal Hyperplasia - Novel Insights into the Diverse

Biological Effects of Perlecan. EuroPCR, May 2010, Paris, France

14. Segev A. The Ovalum CiTop Guidewire: Device Evolution, Peripheral, and Coronary

Applications. 7th International Chronic Total Occlusion Summit, New York, NY,

USA. February 2010

15. Segev A. My most challenging cases. Simultaneous primary PCI during CPR and

systemic cooling. Transcatheter Cardiovascular Therapeutics (TCT), Washington,

DC, USA, September 2010

16. Segev A. Meeting the experts. Presentation of complex cases of transcatheter

aortic valve implantation (TAVI). Transcatheter Cardiovascular Therapeutics (TCT),

Washington, DC, USA, September 2010

17. Segev A. The Ovalum CiTop™ 0.014 guide-wire – device evolution and coronary

and peripheral application. Transcatheter Cardiovascular Therapeutics (TCT),

Washington, DC, USA, September 2010

18. Segev A. Interventional management of ACS in 2010. The 58th Annual Meeting of

The Israel Heart Society, 2011, Tel-Aviv, Israel.

19. Segev A. Transcatheter Aortic Valve Implantation: Patient selection and strategies

for optimal outcomes. International Summit on Imaging and Intervention in

Cardiology (ISIIC), September 2011, Katowice, Poland


of 93

20. Segev A. The remaining unmet needs in coronary interventions. Innovations in

Cardiovascular Interventions (ICI), December 2011, Tel Aviv, Israel

21. Segev A. Strategies to reduce major bleeding in patients with ACS undergoing PCI.

American College of Cardiology (ACC.12) Scientific Sessions, 2012, Chicago, IL, USA

22. Segev A. My Experience with Trans-femoral TAVI. The 61st International Congress

of The European Society of Cardiovascular and Endovascular Surgery – ESCVS,

2012, Dubrovnik, Croatia

23. Segev A. The unmet needs in coronary interventions. Innovations in

Cardiovascular Interventions (ICI), December 2012, Tel Aviv, Israel

24. Segev A. CTO 2013 – still an open issue? Innovations in Cardiovascular

Interventions (ICI), December 2012, Tel Aviv, Israel

25. Segev A. Revisiting Coronary Stent Engineering: Evolution of BioMime &

Advancement to Aura, Morph & Mitsu. Innovations in Cardiovascular

Interventions (ICI), December 2012, Tel Aviv, Israel

26. Segev A. Percutaneous mitral valve interventions – the future is here! French

Society of Cardiology Annual Meeting, January 2013, Paris, France

27. Segev A. Is TAVR an option in patienrs who are poor surgical candidates with

severe aortic regurgitation or a bicuspid valve? What is the international

experience? American College of Cardiology (ACC.13) Scientific Sessions, 2013,

San Francisco, CA, USA

28. Segev A. Current experiences with TAVR treatment for pure aortic regurgitation

and bicuspid AS. American College of Cardiology (ACC.13) Scientific Sessions,

2013, San Francisco, CA, USA

29. Segev A. Current experience with trans-catheter aortic valve implantation. The IV

Congress of Surgeons of the Republic of Kazakhstan, April 2013, Almaty,

Kazakhstan

30. Segev A. CCU aspects of post-TAVI management – What not to be missed. 8th

International Congress on Acute Cardiac Care, June 2013, Jerusalem, Israel

31. Segev A. TAVI in patients with left ventricular assist device. Medtronic global

proctors meeting, June 2013, Rome, Italy


of 93

32. Segev A. Trans-catheter aortic valve implantation in patients with pure aortic

regurgitation. European Society of Cardiology Congress, August 2013, Amsterdam,

The Netherlands

33. Segev A. Start-up programs: Formula for success – the ICI perspective. VIVA,

October 2013, Las Vegas, NE, USA

34. Segev A. Tempral trends in the diagnosis and management of patients with STEMI

2000-2010: The Israel nationwide ACSIS registry and database. 10th International

Congress on Coronary Artery Disease (ICCAD), October 2013, Florence, Italy

35. Segev A. The challenge of carotid artery stenting in symptomatic lesions. 10th

International Congress on Coronary Artery Disease (ICCAD), October 2013,

Florence, Italy

36. Segev A. French Society of Cardiology Annual Meeting, January 2014, Paris, France

37. Segev A. Innovation, technology in cardiology intervention: news from ICI. GISE,

Annual Meeting of the Italian Society of Invasive Cardiology, October 2014, Genoa,

Italy

38. Segev A. New challenges in percutaneous valve interventions. 5th Anglo Israel

Cardiovascular Symposium, October 2014, London, England

39. Segev A. The significance of procedural complications in TAVI vs. sAVR. 3rd Heart

Valve Summit of the Israel Heart Society, October 2014, Tel Aviv, Israel

40. Segev A. Innovation the ICI-Way: Why You Should Come to Tel Aviv. VIVA,

November 2014, Las Vegas, NE, USA

41. Segev A. Trends in the management and outcome of patients with STEMI – Data

from ACSIS. American Heart Association Scientific Sessions, November 2014,

Chicago, IL, USA

42. Segev A. Vascular complications in patients undergoing TAVI – smaller is better.

Innovations in Cardiovascular Interventions (ICI), December 2014, Tel Aviv, Israel

43. Segev A. TAVI Case presentation (meet the giants) - “And Lives a Wolf with Lamb

and Tiger with Capricorn will Lie”. Innovations in Cardiovascular Interventions

(ICI), December 2014, Tel Aviv, Israel

44. Segev A. Vascular complications in patients undergoing TAVI. 9th International

Conference on Acute Cardiac Care, January 2015, Tel Aviv, Israel


of 93

45. Segev A. Trends in the management and outcome of patients with STEMI – Data

from ACSIS. Cardiovascular Research Technologies Meeting (CRT), February 2015,

Washington, DC, USA

46. Segev A. TAVI for non aortic stenosis indications. American College of Cardiology

(ACC.15) Scientific Sessions, March 2015, San Diego, CA, USA

47. Segev A. The future of structural heart interventions. China Interventionl

Therapeutics (CIT), March 2015, Beijing, China

48. Segev A. The story of an Israeli start-up – Biosense Webster. China Innovations in

Cardiology (CIC), June 2015, Nanjing, China

49. Segev A. Collagenase for the treatment of coronary CTOs – from a crazy idea to

phase-2 clinical trial. China Innovations in Cardiology (CIC), June 2015, Nanjing,

China

50. SegevA. European Society of Cardiology (ESC) Congress, August 2015, London, UK

51. Segev A. Current limitations and future directions of transcatheter valvular

interventions. 11th International Congress on Coronary Artery Disease (ICCAD),

November 2015, Florence, Italy

52. Segev A. Future solutions for mitral and tricuspid valve implantation and repair.

4th Heart Valve Summit of the Israel Heart Society, November 2014, Tel Aviv, Israel

53. Segev A. Acute stroke interventions – the role of the interventional cardiologist.


54. Segev A. Current limitations of transcatheter aortic valve implantation.


55. Segev A. Percutaneous treatment of tricuspid regurgitation – Where do we stand?

Heart Valve Society (HVS) Meeting, March 2016, New York, NY, USA

56. Segev A. TAVR for regurgitant aortic bioprosthesis. Heart Valve Society (HVS)

Meeting, March 2016, New York, NY, USA

57. Segev A. TAVR in Israel. American College of Cardiology (ACC.16) Scientific

Sessions, March 2016, Chicago, IL, USA

58. Segev A. Immediate revascularization after OHSD and ROSC - PRO. The 2nd

Conference of the Israel Society of Rescusitation. May 2016, Ramat Gan, Israel

59. Segev A. TAVI in a patient with a significant left anterior descending lesion. How

would I treat? EuroPCR. May 2016. Paris, France


of 93

60. Segev A. Urgent TAVI for deteriorating critical AS with extensive anterior wall MI.

How would I treat? EuroPCR. May 2016. Paris, France

61. Segev A. The changing world of biomedical innovation: the digital revolution.

EuroPCR. May 2016. Paris, France

62. Segev A. TAVI – Are we doing too many futile cases? European Society of

Cardiology Congress. August 2016. Rome, Italy

63. Segev A. Valcare mitral annuloplasty – from basic concept to early clinical

experience. London PCR Valves. Sep 2016. London, UK

64. Segev A. Conduction Disturbances after TAVI: How to Monitor and when to

Implant a Permanent Pacemaker. Annual Meeting of ACCA. Oct 2016. Lisbon,

Portugal

65. Segev A. Optimization of TAVI outcomes - Better Patient Selection and Prevention

of Complications. Innovations in Cardiovascular Interventions (ICI), December


66. Segev A. Transcatheter aortic valve replacement: are we doing too many futile

procedures? Innovations in Cardiovascular Interventions (ICI), December 2016, Tel

Aviv, Israel

67. Segev A. My Crazy TAVI case. Trans-catheter aortic valve and a mechanical mitral

valve – Not good mates! Innovations in Cardiovascular Interventions (ICI),

December 2016, Tel Aviv, Israel

68. Segev A. Latest clinical update on TAVI. The 5th Heart Valve Summit of the Israel

Heart Society, January 2017, Tel Aviv, Israel

69. Segev A. A 34y old patient with failed aortic bioprosthesis. The 5th Heart Valve

Summit of the Israel Heart Society, January 2017, Tel Aviv, Israel

70. Segev A. Risk and management of antiplatelet therapy in perioperative patients.

10th International Conference on Acute Cardiac Care, January 2015, Tel Aviv, Israel

71. Segev A. TAVR – Insights from the Israeli Registry. Cardiology Grand Rounds,

Sunnybrook Healthcare Center, January 2017, Toronto, Canada

72. Segev A. NOACs pre- and post-PCI. Israel Heart Society Annual Meeting, April


73. Segev A. ACS and Heart Failure: Timing and Revascularisation Strategy. European

Society of Cardiology Congress, August 2017, Barcelona, Spain


of 93

74. Segev A. What are the remaining unmet needs in coronary interventions.


75. Segev A. Balloon pulmonary angioplasty for the treatment of CTEPH. Innovations

in Cardiovascular Interventions (ICI), December 2017, Tel Aviv, Israel

76. Segev A. TAVI – When it is futile? Innovations in Cardiovascular Interventions (ICI),

December 2017, Tel Aviv, Israel

77. Segev A. TAVI – State of the art 2018. The 65th Scientific Meeting of the Israel Heart

Society – Joint session with the ESC, April 2018, Tel Aviv, Israel

78. Segev A. Start-up nation: Israel's model of biomedical innovations. TCT Russia,

May 2018, Moscow, Russia

79. Segev A. New concepts in minimal invasive therapy of heart failure. TCT Russia,

May 2018, Moscow, Russia

80. Segev A. Complete or incomplete revascularization in patients with cardiogenic

shock. 11th International Conference of Acute Cardiac Care, June 2018, Tel Aviv,

Israel

81. Segev A. Trans-catheter aortic valve implantation: When is it too late? 11th

International Conference of Acute Cardiac Care, June 2018, Tel Aviv, Israel

82. Segev A. Difficult treatment decisions in patients with severe aortic valve stenosis:

Who is too frail to have TAVl? European Society of Cardiology Congress, August

2018, Munich, Germany

83. Segev A. TAVI in 2019: Insights from the Isreali Multicenter TAVI registry. IX

Congress on Novel Frontiers in Cardiovascular Medicine, February 2019, Lisbon,

Portugal.

84. Segev A. New developments in percutaneous treatment of valvular heart disease.

IX Congress on Novel Frontiers in Cardiovascular Medicine, February 2019, Lisbon,

Portugal

85. Segev A. Basic considerations in CTO revascularization. Jerusalem CTO Summit.

March 2019, Jerusalem, Israel

86. Segev A. Overview of inter-atrial shunt devices in herat failure. ACC.19, March

2019, New Orleans, LO, USA.

87. Segev A. My vision of the cath lab of the future. TCT Russia, June 2019, Moscow,

Russia


of 93

88. Segev A. Resurgence of Device-Based Therapy for Heart Failure. TCT Russia, June

2019, Moscow, Russia

89. Segev A. Clinical predictors for procedural stroke and implications for embolic

protection device during TAVI: Results from the multicenter Transcatheter Aortic

valve implantation in hoSpital stroKe (TASK) study. TCT, September 2019, San

Francisco, CA, USA.

90. Segev A. Risk stratification in patients undergoing TAVR – beyond STS. Virtual

TAVR Academy, Meril Life, July 2020, India

D.2. PAPERS PRESENTED IN INTERNATIONAL SCIENTIFIC MEETINGS PUBLISHED AS

ABSTRACTS:

1) Segev A, Aviezer D, Gross Z, Yayon A.

Inhibition of Vascular Smooth Muscle Cell Proliferation by a Novel Class of Fibroblast

Growth Factor Antagonists.

American Heart Association (AHA), 71st Scientific Sessions, 1998, Dallas, TX, USA.

Circulation 1998:

2) Lau HK, Segev A, Sparkes JA, Teitel JM, Chisholm RJ, Strauss BH.

Thrombin-activable fibrinolysis inhibitor (TAFI): A novel predictor of angiographic


American Heart Association (AHA), 75th Scientific Sessions, 2002, Chicago, IL, USA.

Circulation 2002


EA, Strauss BH.



Canadian Cardiovascular Society Congress (CCSC), 2003, Toronto, ON, Canada. Can J

Cardiol 2003;19(Suppl A):136A

4) Segev A, Lau HK, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH.

Thrombin-activatable fibrinolysis inhibitor (TAFI): A novel predictor of angiographic



Cardiol 2003;19(Suppl A):189A


of 93

5) Segev A, Goldman L, Qiang B, Nili N, Butany J, Sparkes JD, Jackson ZS, Eskandarian

MR, Virmani R, Strauss BH.

Collagenase plaque digestion for facilitating guidewire crossing in chronic total arterial

occlusions.


Cardiol 2003:19(Suppl A):170A

6) Segev A, Ellis MH, Segev F, Friedman Z, Reshef T, Pauzner H, David D.

High prevalence of thrombophilia among young patients with myocardial infarction

and few conventional risk factors.

American Heart Association (AHA), 76th Scientific Sessions, 2003, Orlando, FL, USA.

Circulation 2003: Finalist in poster competition in clinical sciences.


EA, Strauss BH.



American College of Cardiology (ACC), 53rd Annual Scientific Sessions, 2004, New

Orleans, LA, USA. J Am Coll Cardiol 2004

8) Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG.

Predictors and one-year outcome of major bleeding in patients with non-ST elevation

acute coronary syndromes: Insights from the Canadian Acute Coronary Syndrome

Registries.

American Heart Association (AHA), 77th Scientific Sessions, 2004, New Orleans, LA,

USA.

9) Segev A, Nili N, Qiang B, Wong A, Pasterkamp G, Pillarisetti S, Virmani R, Strauss BH.

Stents coated with a perlecan-inducing compound significantly reduce intimal

hyperplasia in a rabbit iliac in-stent restenosis model - novel insights into the diverse

biological effects of perlecan.

American Heart Association (AHA), 77th Scientific Sessions, 2004, New Orleans, LA,

USA.

10) Burstein JM, Segev A, Strauss BH, Cheema A, Cantor WJ, Kutryk MB, Charron T,

Sheth T, Chisholm RJ.

Stenting of bifurcation lesions using drug eluting stents.


of 93

Canadian Cardiovascular Society Congress (CCSC), 2005, Montreal, QB, Canada. Can J

Cardiol 2005:

11) Charron T, Bang A, Qiang B, Puley G, Segev A, Shakoor S, Freedman J, Strauss BH.

No-Reflow after coronary distal embolization: role of platelet activation and

interactions between platelets and white blood cells.

Canadian Cardiovascular Society Congress (CCSC), 2005, Montreal, QB, Canada. Can J

Cardiol 2005

12) Segev A, Elian D, Matetzky S, Guetta V.

Thrombus aspiration during primary percutaneous coronary intervention in acute ST-

elevation myocardial infarction.

9th International Congress on Coronary Artery Disease (ICCAD), October 2009, Prague,

Czech Republic.

13) Segev A.

The Ovalum CiTop™ Guidewire for recanalization of chronic total occlusion.

Transcatheter Cardiovascular Therapeutics (TCT), San Francisco, CA, USA. September

2009

14) Segev A.

Primary PCI in patients with multi-vessel disease Beyond the culprit lesion?

EUROPCR, Paris, France. May 2010

15) Segev A, Nili N, Osheov AB, Qiang B, Wong AJ, Pillarisetti S, Strauss BH.

A Perlecan-Inducing Compound Significantly Inhibits Smooth Muscle Cell Function and

In-stent Intimal Hyperplasia - Novel Insights into the Diverse Biological Effects of

Perlecan.

EUROPCR, Paris, France. May 2010

16) Beigel R, Segev A, Goitein O, Brosh S, Oieru D, Konen E, Asher E, Hod H, Matetzky

S.

Non obstructive coronary artery disease upon multidetector computed tomography

in patients presenting with acute chest pain - Does it matter?

European Society of Cardiology Congress, Stockholm, Sweden. 2010

17) Fink N, Kuperstein R, Segev A, Guetta V, Sternik L, Raanani E, Feinberg MS.


of 93

Early and mid term hemodynamic profile of the percutaneous CoreValve™ compared

ro surgical bioprosthesis for the treatment of severe aortic stenosis – a single center

experience.

American College of Cardiology (ACC), 60th Annual Scientific Sessions, 2011, New


18) Buber Y, Laish- Farkash A, Koren M, Fefer P, Segev A, Dulman R, Hod H, Matetzky

S.

The Pattern of Cardiac Troponin Elevation in Patients Undergoing Primary

Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction and its

Implications for Patients' Outcomes.

American College of Cardiology (ACC), 60th Annual Scientific Sessions, 2011, New


19) Hamdan A, Guetta V, Konen E, Raanani E, Segev A, Spigelstein D, Hay I, Goitein O,

Eldar M, Schwammenthal E.

Assessing aortic annuklar dynamics by four-dimensional multislice computed

tomography: implications for transcatheter aortic valve implantation.

European Society of Cardiology Congress, Paris, France, August 2011. Eur Heart J 2011

20) Dvir D, Laborde JC, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, Descoutures

F, Moat NE, Hengstenberg C, Bekerdjian R, Lefevre T, Nissen H, Hernández JM, Roy D,

De Marco F, Teles R, Segev A, Baumbach A, Dumonteil N, Fiorina C, Ioanes D,

Napodano M, Tchetche D, Ussia GP, Merx MW, Abdel-Wahab M, Kornowski R.

Transcatheter aortic-valve implantation for the treatment of degenerative

bioprosthetic surgical valves: results from the Global VIV (Valve-in-Valve) Registry.

Transcatheter Cardiovascular Therapeutics (TCT), San Francisco, CA, USA. November

2011. J Am Coll Cardiol 2011

21) Hamdan A, Guetta V, Konen E, Goitein O, Segev A, Raanani E, Spiegelstein D, Hay

I, DiSegni E, Eldar M, Schwammenthal E.

Deformation dynamics and mechanical properties of the aortic annulus by four-

dimensional computed tomography - insights unto the functional anatomy of the

aortic valve complex and implications for transcatheter aortic valve therapy.

American Heart Association (AHA) Scientific Meeting, Orlando, FL, USA, Novenber

2011. Circulation 2011


of 93

22) Beigel R, Brosh S, Goitein O, Gutman E, Segev A, Konen E, Oieru D, Hod H,

Matetzky S.

The significance of non-obstructive coronary artery disease upon multi-detector

computed tomography in patients presenting with acute chest pain.

American College of Cardiology (ACC.12) Scientific Sessions, 2012, Chicago, IL, USA. J

Am Coll Cardiol 2012

23) Moriel M, Matetsky S, Segev A, Kornowski R, Danenberg H, Bubyr L, Goldenberg

I, Tzivoni D, Gottlieb S.

Thrombus aspiration in patients with ST-elevation myocardial infraction undergoing

primary percutaneous coronary intervention - Insights from the Acute Coronary

Syndrome Israeli Survey 2010.



24) Segev A, Spiegelstein D, Fefer P, Shinfeld A, Hay I, Raanani E, Guetta V.

Off-label use of trans-catheter aortic valve implantation.

European Society of Cardiology Congress, Munich, Germany, August 2012. Eur Heart

J 2012

25) Rozen G, Fefer P, Shinfeld A, Sternik L, Guetta V, Levin S, Malachy A, Raanani E,

Segev A.

Surgical aortic valve replacement for severe aortic stenosis in the era of transcatheter

implantation.

European Society of Cardiology Congress, Munich, Germany, August 2012. Eur Heart

J 2012

26) Sabbag A, Goldenberg I, Segev A.

Recent temporal trends in the presentation, management, and outcome of women

hospitalized with acute coronary syndromes.

American College of Cardiology (ACC.13) Scientific Sessions, 2013, San Francisco, CA,

USA. J Am Coll Cardiol 2013

27) Moriel M, Matetzky S, Segev A, Medina A, Kornowski R, Danenberg H, Gavrielov-

Yusim N, Goldenberg I, Tzivoni D, Gottlieb S.


of 93

The impact of thrombus aspiration on 1-year mortlaity in primary PCI for ST-elevation

myocardial infarction, ACSIS 2010 experience. European Society of Cardiology Congress, Amsterdam, The Netherlands, August 2013.

Eur Heart J 2013

28) Maor E, Grossman Y, Balmor RG, Segel M, Fefer P, Ben-Zekry S, Buber Y, DiSegni

E, Ben-Dov I, Segev A.

Role of Exercise Hemodynamics in unmasking of diastolic dysfunction among patients

with pulmonary hypertension.

American College of Cardiology (ACC.14) Scientific Sessions, 2014, Washington, DC,


29) Medvedofsky D, Klempfner R, Fefer P, Chernomordik F, Hamdan A, Hay I,

Goldenberg I, Raanani E, Guetta V, Segev A.

The Significance of Pulmonary Arterial Hypertension Pre- and Post-Transfemoral

Aortic Valve Implantation for Severe Aortic Stenosis.

American College of Cardiology (ACC.14) Scientific Sessions, 2014, Washington, DC,


30) Bogdan A, Segev A, Fefer P. Hay I, Hamdan A, Feinberg M, Spiegelstein D, Raanani

E, Davh R, Bogdan S, Asher E, Guetta V, Barbash I.

Post-procedural serum albumin predicts late mortlaity in TAVI patients.

EuroPCR, 2014, Paris, France. Eurointervention 2014.

31) Bodgan A, Guetta V, Barbash I, Hay I, Hamdan A, Feinberg M, Speigelstein D,

Raanani E, Mandelbaum T, Bogdan S, Asher E, Segev A, Fefer P.

Intra-procedural heart rate variation predicts late mortality following TAVI.

EuroPCR, 2014, Paris, France. Eurointervention 2014.

32) Sabbag A, Matetzky S, Iakobishvili Z, Gottlieb S, Porter A, Moriel M, Goldenberg I,

Segev A.

Gender differences affecting outcome in young patients (<55y) with acute coronary

syndromes.

European Society of Cardiology Congress, 2014, Barcelona, Spain. Eur Heart J 2014

33) Hamdan A, Guetta V, Konen E, Raanani E, Klempner R, Segev A, Goitein O,

Medvedovsky D, Eldar M, Schwammenthal E.

http://www.abstractsonline.com/pp8/#!/3392/presentation/29047

http://www.abstractsonline.com/pp8/#!/3392/presentation/29047


of 93

Computed-tomographic assessment of membranous septal anatomy for risk

prediction of atrioventricular block associated with transcatheter aortic balloon

expandable valve implantation.


34) Sabbag A, Matetzky S, Gottlieb S, Atar S, Zahger D, Iakobishvili Z, Goldenberg I,

Segev A.

Nation-wide real-life implementation of primary percutaneous coronary intervention

strategy improves survival in patients with ST-elevation myocardial infarction.


35) Simonato M, Duncan A, Webb J, Bapat V, Lefevre T, Attizzani G, Maria Hernandez

J, Lemos P, Welsh R, Iadanza A, Salizzoni S, Agrifoglio M, Presbitero P, Bruschi G,

Casselman F, Himbert D, Makkar R, Salemi A, Hellig F, Gafoor S, Chakravarty T, Segev

A, Finkelstein A, Kornowski R, Dvir D.

Stentless vs. Stented Aortic Valve-in-Valve Implantation: Insights from the Valve-in-

Valve International Data Registry (VIVID).

Transcatheter Cardiovascular Therapeutics (TCT), San Francisco, CA, USA. November

2015. J Am Coll Cardiol 2015



Outcome after primary percutaneous coronary intervention for ST elevation

myocardial infarction in nanogenerians. European Society of Cardiology Congress,

2016, Rome, Italy. Eur Heart J 2016

37) Landes U, Barsheshet A, Finkelstein A, Guetta V, Assali A, Halkin A, Vaknin-Assa H,

Segev A, Bental T, Ben-Shoshan J, Barbash IM, Kornowski R.

Temporal trends in transcatheter aortic valve implantation in Israel 2008-2014:

patient characteristics, procedural issues and outcome.

European Society of Cardiology Congress, 2016, Rome, Italy. Eur Heart J 2016

38) Witberg G, Barbash I, Finkelstein A, Assali A, Segev A, Halkin A, Fefer P, Ben-

Shoshan J, Konigstein M, Guetta V, Kornowski R, Barsheshet A.

Aortic valve gradient and mortlaity in patients undergoing transcatheter aortic valve

implantation for severe aortic stenosis.

European Society of Cardiology Congress, 2016, Rome, Italy. Eur Heart J 2016


of 93

39) Brodov Y, Konen E, Di Segni M, Samooha D, Novikov I, Barbash I, Regev E, Guetta

V, Segev A, Fefer P, Grossman Y, Chernomordik F, Glikson M, Goitein O.

Impact of different calcium locations of mitral annulus and aortic valve cusps on risk

of conduction disturbances after transcatheter aortic valve implantation.



40) Witberg G, Regev E, Chen S, Assali A, Barbash I, Planer D, Vaknin Assa H, Guetta V,

Zeniou V, Orvin K, Danenberg H, Segev A, Kornowski R.

The association of coronary artery disease severity and pre procedural completeness

of revascularization on mortality in patients undergoing transcatheter aortic valve

replacement.



41) Grossman Y, Barbash I, Berkovitch A, Chernomordik F, Brodov Y, Segev A, Asher

E, Elian D, Younis A, Ben Zekry S, Guetta V, Fefer P.

Long term results of access related vascular complications following TAVI.

Transcatheter Cardiovascular Therapeutics (TCT), Denver, CO, USA. November 2017. J


42) Biton D, Grossman Y, Finkelstein A, Brodov Y, Fefer P, Barbash I, Landes U, Arbel

Y, Guetta V, Segev A.

Trans-catheter aortic valve replacement in the presence of mitral prosthesis or ring.



43) Baldetti L, Giannini F, Latib A, Tchetche D, De Biase C, Tarantini G, Fraccaro C,

Tamburino C, Barbanti M, Van Mieghem N, Segev A, Petronio AS, Mangieri A,

Regazzoli D, Ancona M, Colombo A.

Outcome Of Patients Undergoing Trans-Catheter Implantation Of Aortic Valve With

Previous Mitral Valve Prosthesis (Optimal Study).



44) Fefer P, Kohen S, Segev A, Elian D, Asher E, Chernomordik F, Grossman Y,

Berkovitch A, Ben Zekry S, Barbash I, Guetta V.


of 93

Rapid ventricular pacing is associated with worse outcomes after trans-catheter aortic

valve replacement.



45) Itzhaki Ben Zadok O, Orvin K, Finkelstein A, Barbash IM, Danenberg H, Segev A,

Guetta V, Halkin A, Planer D, Bental T, Vaknin Assa H, Assali A, Barsheshet A, Kornowski

R.

Temporal trendes in sex-related differences in clinical characteristics and oytcome of

patients undergoing TAVI – data from a national TAVI registry.

European Society of Cardiology Congress, 2018, Munich, Germany. Eur Heart J 2018

46) Chernomordik F, Asher E, Tal S, Fefer P, Segev A, Beigel R, Matetzky S.

Comparison of platelet inhibition in patients with STEMI vs. NSTEMI after a laoding

dose of swallowed vs. chewed ticagrelor.


48) Zusman O, Landes U, Barbash IM, Finkelstein A, Danenberg H, Segev A, Guetta V,

Orvin K, Assali A, Barsheshet A, Kornowski R.

TAVI futility risk model: insights on a national registry.


49) Younis A, Orvin K, Nof E, Barbash IM, Guetta V, Segev A, Berkovitz A, Fefer P,

Glikson M, Vaknin H, Assali A, Kornowski R, Goldenberg I, Beinart R.

Effects and safety of beta-blocker withdrawl among patients undergoing TAVR.


50) Kuperstein R, Michlin M, Barbash I, Mazin I, Brodov Y, Segev A, Fefer P, Arad M,

Ben Zekry S, Schwammenthal E.

Pseudo-discordance mimicking low flow low gradient AS in TAVR patients with severe

symptomatic aortic stenosis.

European Society of Cardiology Congress, 2019, Paris, France. Eur Heart J 2019

51) Nassar M, Perlman G, Arow Z, Lessick J, Segev A, Assaali A, Danenberg H, Goitein

O, Vaknin-Assa H, Orvin K, Sabtan O, Finkelstein A, Banai S, Kornowski R, Hamdan A.

Differences in valve morphology and aoortopathy between patients with bicuspid and

tricuspid aortic valves: a computed tomography study.



of 93

52) Younis A, Matetzky S, Masalha E, Chernomordik F, Afel Y, Fardman A, Goitein O,

Ben Zekry S, Grupper A, Segev A, Beigel R.

Sex differences in clinical presentation and in hospital outcomes among myocarditis

and peri-myocarditis patients.


53) Berkovitch A, Barbash I, Finkelstein A, Assali AR, Danenberg H, Fefer P, Maor E,

Zhitomirsky S, Orvin K, Steinvil A, Barsheshet A, Halkin A, Guetta V, Kornowski R, Segev

A.

Validation of the cardiac damage classification and additional effects of albumin in a

large cohort of patients undergoing transcatheter aortic valve replacement.


D.3. OTHER ABSTRACTS IN SCIENTIFIC MEETINGS:

1) Segev A, Barenboim E, Schneider M, Mekori YA.

Light Chain Myeloma – 3 Different Aspects of a Rare Disease.

Annual Meeting of the Israel Internal Medicine Society, 1998, Tel-Aviv, Israel

2) Segev A, Bental T, Rozenbaum E, Arbel J, Pauzner H, Bakst A, David D.

Gender Differences in Mortality of Elderly Patients After Percutaneous Coronary

Interventions.

The 48th Annual Conference of the Israel Heart Society, 2001, Jerusalem, Israel

3) Segev A, Rozenbaum EA, Arbel J, Bental T, Bakst A, David D.

Treatment of in-stent restenosis with excimer laser ablation and rotational

atherectomy – Meir Hospital experience.


4) Bental T, Arbel J, Rozenbaum EA, Segev A, Bakst A, David D.

Primary PCI – Meir Hospital experience.


5) Segev A, Behar S, Boyko V, David D.

The potential benefit of pre-event treatment with ACE inhibitors or beta-blockers in

patients with acute myocardial infarction – data from the ARGAMI study.

The 49th Annual Conference of the Israel Heart Society, 2002, Tel-Aviv, Israel

6) Segev A, Ellis MH, Friedman Z, Reshef T, Pauzner H, David D.


of 93

Hypercoagulability profile of young patients in the course of a first myocardial

infarction.

The 49th Annual Conference of the Israel Heart Society, 2002, Tel-Aviv, Israel

7) Segev A, Chisholm RJ.

Saphenous vein graft perforation – case presentation – final challenging cases

competition.

Transcatheter Cardiovascular Therapeutics (TCT), 2003, Washington, DC, USA

8) Segev A, Nili N, Qiang B, Wong A, Paterkamp G, Pillarisetti R, Strauss BH.

Stents coated with a perlecan inducing compound significantly reduce intimal

hyperplasia in a rabbit iliac in-stent restenosis model. 5th International Meeting on

Interventional Cardiology: Frontiers in Interventional Cardiology, 2003, Tel-Aviv, Israel

9) Segev A, Lau HK, Hegele RA, Sparkes JA, Teitel JM, Chisholm RJ, Strauss BH.

Thrombin-activable fibrinolysis inhibitor (TAFI): A novel predictor of angiographic


5th International Meeting on Interventional Cardiology: Frontiers in Interventional

Cardiology, 2003, Tel-Aviv, Israel. Best Abstract Award winner (1000US$)

10) Segev A, Strauss BH, Tan M, Langer A, Goodman SG.

Admission Heart Failure in Patients with Non ST-Elevation Acute Coronary Syndromes:

Predictors and Long-Term Outcome. The 52nd Annual Meeting of The Israel Heart

Society, 2005, Tel-Aviv, Israel.

11) Segev A, Strauss BH, Tan M, Buller CE, Langer A, Goodman SG.

Risk Factors and Outcome of In-Hospital Ischemic Stroke in Patients with Non-ST

Elevation Acute Coronary Syndromes.

The 52nd Annual Meeting of The Israel Heart Society, 2005, Tel-Aviv, Israel.

12) Segev A, Qiang B, Nili N, Giordano FJ, Strauss BH.

Inhibition of Neo-Intimal Hyperplasia after Stenting by Over-Expression of p15 – a

Memeber of the INK4 Family of CDK Inhibitors.


13) Segev A, Nili N, Qiang B, Pasterkamp G, Virmani R, Strauss BH.

Stents coated with a perlecan-inducing compound significantly reduce intimal

hyperplasia in a rabbit iliac in-stent restenosis model - Novel insights into the diverse

biological effects of perlecan.


of 93


14) Segev A, Strauss BH, Tan M, Langer A, Goodman SG.

Predictors and One-Year Outcome of Major Bleeding in Patients with Non-ST Elevation

Acute Coronary Syndromes: Insights from the Canadian Acute Coronary Syndrome

Registries.


15) Segev A, Matetzky S, Tan M, Elian D, Langer A, Goodman SG.

Outcome of Patients with Acute Coronary Syndromes Enrolled in Clinical Studies.

The 53rd Annual Meeting of The Israel Heart Society, 2006, Tel-Aviv, Israel.

16) Segev A, Matetzky S, Marai I, Elian D, Agranat O, Har-Zahav Y, DiSegni E, Rath S,

Hod H, Guetta V.

Thrombus Aspiration during Primary Percutaneous Coronary Intervention in Acute ST-

Elevation Myocardial Infarction.


17) Segev A, Kachel E, Nili N, Raanani E, Strauss BH.

Positive Remodeling in Venous Bypass Grafts: Novel Implications for Vein Graft

Disease.


18) Kachel E, Kassif Y, Raanani E, Strauss BH, Segev A.

Positive Remodeling in Venous Bypass Grafts: Novel Implications for Vein Graft

Disease. Ami Cohen Award Finalist.

The 54th Annual Meeting of The Israel Heart Society, 2007, Tel-Aviv, Israel.

19) Amsalem Y, Guetta V, Laish-Farkash A, Segev A.

Comparison of Late versus Early Stent Thrombosis: 5-Year Experience from a Large

Unselected Population.

The 55th Annual Meeting of The Israel Heart Society, 2008, Tel-Aviv, Israel

20) Laish-Farkash A, Hod H, Segev A, Sela B, Amsalem Y, Michailidis A, Matetzky S.

The Value of Troponin-I Curve after Primary PCI for ST Elevation Myocardial Infarction.


21) Segev A, Danenberg H, Schwammenthal E, Gilon D, Guetta V, Lotan C.

Percutaneous Implantation of the Self-Expandable CoreValve in Patients with Severe

Aortic Stenosis: The Technique.


of 93


22) Parikh K, Shah A, Chag M, Scheinowitz M, Segev A.

Ovalum CiTopTM: A Novel Guidewire for crossing Chronic Total Occlusion in Coronary

Artery Disease patients – First-in-Man Experience.


23) Belenky A, Litvin S, Scheinowitz M, Segev A.

The New 0.014” CiTop™ Guidewire for the Treatment of Chronic Total Occlusions in

Peripheral Arteries: Results of the First-in-Man Randomized Clinical Study.


24) Danenberg H, Segev A, Schwammenthal E, Hod H, Zfat D, Gilon D, Lotan C, Guetta

V.

Percutaneous Implantation of the Self-Expandable CoreValve for High-risk

Patients with Severe Aortic Stenosis: Initial Israeli Experience.


25) Segev A, Fefer P, Dahulah A, Sparkes J, Chisholm R, Strauss BH.

Post-Percutaneous Coronary Intervention Creatine Kinase Elevation: An Angiographic

Complication Predicts a Worse 1-Year Outcome.


26) Segev A, Schwammenthal Y, Orion D, Guetta V.

Carotid Stenting for "Restenosis" after Surgical Endarterectomy.


27) Segev A, Guetta V.

Thrombus aspiration during primary percutaneous coronary intervention in acute ST-

elevation myocardial infarction.

9th International Congress on Coronary Artery Disease (ICCAD), October 2009, Prague,

Czech Republic.

28) Danenberg H, Finkelstein A, Kornowski R, Segev A, Dvir D, Gilon D, Keren G, Sagie

A, Feinberg M, Schwammenthal E, Banai S, Lotan C, Guetta V.

Percutaneous Implantation of the Self-Expandable CoreValve for High-Risk Patients

with Severe Aortic-Valve Stenosis: Early Israeli Experience.


29) Segev A, Guetta V, Bloom A, Gerniak A, Lotan C, Danenberg H.

http://www.israel-heart.org.il/annual09/P2p18.pdf




http://www.israel-heart.org.il/annual09/ec2p2.pdf


of 93

Peripheral Vascular Complications following Transcatheter Aortic Valve Implantation:

New Challenges to the Interventional Cardiologist.


30) Segev A, Gottlieb S, Atar S, Roth A, Nahir M, Mosseri M, Danenberg H, Kornowski

R, Behar S.

Trends of Coronary Procedures among Patients with Acute Coronary Syndrome in

Israel (ACSIS 2002-2008).


31) Fefer P, Segev A, Elian D, Yonash M, Har Zahav Y, Agranat O, Rath S, Guetta V.

Unprotected Left Main Stenting: An Israeli Perspective.


32) Fefer P, Segev A, Tsimikas S, Strauss BH.

Oxidized Phospholipids and Lipoprotein(a) Response Following Successful

Percutaneous Revascularization of Chronically Occluded Coronary Arteries.


33) Fefer P, Chisholm R, Sparkes JD, Strauss BH, Guetta V, Segev A.

Visible Angiographic Complications Predict Short and Long-Term Outcomes in Patients

with Post-Procedural Creatine-Phosphokinase Elevation.


34) Segev A, Schwammenthal I, Orion D, Tsabari R, Tanne D, Guetta V.

Carotid Artery Stenting: Evaluation of a Neurology-Cardiology Team Approach.


35) Beigel R, Segev A, Goitein O, Brosh S, Oieru D, Konen E, Asher E, Hod H, Matetzky

S.

Non Obstructive Coronary Artery Disease upon Multidetector Computed

Tomography in Patients Presenting with Acute Chest Pain - Does it Matter?


36) Buber Y, Laish-Farkash A, Segev A, Fefer P, Koren-Morag N, Eldar M, Hod H,

Matetzki S.

Clinical Implications of cTnI Elevation Curve following Primary Percutaneous Coronary

Intervention.


http://www.israel-heart.org.il/annual2011/S1_5.pdf

http://www.israel-heart.org.il/annual2011/S1_5.pdf


of 93

37) Hamdan A, Guetta V, konen E, Raanani E, Segev A, Goitein O, Spiegelstein D, Hay

I, Eldar M, Schwammenthal E.

Assessing aortic annular dynamics by four-dimensional multislice CT: Implications for

TAVI.


38) Goldenberg G, Segev A, Dvir D, Kusneic H, Hay I, Finkelstein A, Kornowski R, Glikson

M, Guetta V.

Predictors of atrio-ventricular conduction abnormalities requiring permanent

pacemaker after TAVI.


39) Fink N, Kuperstein R, Segev A, Guetta V, Sternik L, Raanani E, Feinberg MS.

Hemodynamic profile of the percutaneous Corevalve ™ compared to surgical aortic

valve replacement.


40) Jaffe R, Lewis BS, Guetta V, Khader N, Halon D, Segev A.

Unprotected left main coronary artery stenting in high-risk patients with severe aortic

stenosis.


41) Asher E, Matetzky S, Fink N, Naimushin A, DiSegni E, Hod H, Agranat O, Guetta V,

Har-Zahav Y, Segev A, Feinberg M, Elian D.

Left ventricular apical ballooning outcomes and long term follow up, the Sheba

experience 2002-2010.


42) Moriel M, Matetzky S, SegevA, Kornowski R, Danenberg H, Bubyr L, Goldenberg I,

Tzivoni D, Gottlieb S.

Thrombus aspiration in STEMI patients undergoing primary PCI – Insights from ACSIS

2010.


43) Fefer P, Matetzky S, Kornowski R, Danenberg H, Gottlieb S, Bubyr L, Zahger D,

Meerkin D, Cafri C, Atar S, Segev A

Radial intervention in patients with acute coronary syndromes – results from ACSIS

PCI 2010.


of 93


44) Beigel R, Matetzky S, Fefer P, Danenberg H, Gottlieb S, Kornowski R, Zahger D,

Goldenberg I, Segev A

Predictors of high-risk angiographic findings in patients with non ST-elevation ACS.


45) Goitein O, Di-Segni E, Konen E, Eshet Y, Guetta V, Segev A, Hamdan A.

The Additive value of CT prior to transcatheter aortic valve implantation (TAVI)

procedure.


46) Jaffe R, Finkelstein A, Lewis B, Guetta V, Khader N, Rubinshtein R, Halon D, Segev

A.

Left main stenting in patients with severe aortic stenosis prior to percutaneous valve

interventions.


47) Rozen G, Fefer P, Malachy A, Shinfeld A, Sternik L, Guetta V, Raanani E, Segev A.

Surgical aortic valve replacement for aortic stenosis in the era of transcatheter

implantation.


48) Danenberg H, Finkelstein A, Guettta V, Almagor Y, Nader K, Kerner A, Cafri C,

George J, Rosenman Y, Segev A, Kornowski R

Transcatheter aortic valve implantation in Israel 2011: Preliminary results of the

national Israeli ongoing registry.


49) Beigel R, Brosh S, Goitein O, Guttman E, Segev A, Oeiru D, Konen E, Gerber Y, Hod

H, Matetzky S

Non-obstructive coronary artery disease upon computed tomography in patients with

acute chest pain.


50) Herscovici R, Hod H, Matetzky S, Kuperstein R, Feinberg M, Grupper A, Segev A.

The effect of systemic hypothermia on myocardial salvage in patients with STEMI and

primary PCI.



of 93

51) Shinfeld A, Guetta V, Segev A, Hai I, Spiegelstein D, Garniec A, Rimon U, Khaitovich

B, Preisman S, Nachum ER, Raanani E.

Hybrid cardiac operating room: First year experience


52) Moriel M, Matetzky S, Segev A, Medina A, Kornowski R, Danenberg H, Gevrielov-

Yusim N, Goldenberg I, Tzivoni D, Gottlieb S.

The Impact of Thrombus Aspiration on 1-year Mortality in Primary PCI for ST-elevation

Myocardial Infarction, ACSIS 2010 Experience.

The 60th Annual Meeting of The Israel Heart Society, 2013, Jerusalem, Israel

53) Goitein O, Lotan E, Fefer P, Segev A, DiSegni E, Eshet Y, Hamdan A, Konen E,

Matetzky S.

What between Health in Coronary CT Angiography and Catheterization in Patients

Undergoing Coronary Stenting


54) Hamdan A, Guetta V, Raanani E, Konen E, Klempfner R, Segev A, Medvedovsky D,

Goitein O, Eldar M, Schwammenthal E.

Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve

Implantation.


55) Segal M, Balmor R, Yaron P, Fefer P, Ben-Dov I, Segev A.

Acute Hemodynamic Response to Inhaled Iloprost (Ventavis™) in Patients with

Pulmonary Hypertension Out of Proportion to Left Ventricular Filling Pressure


56) Herscovici R, Beigel R, Koifman E, Fefer P, Segev A, Guetta V, Hod H, Matetzky S.

The Variability of the Anti-platelet Effect of Prasugrel in Patients with ST- Elevation

Myocardial Infarction undergoing Primary Angioplasty


57) Koifman E, Beigel R, Fefer P, Hershkovici R, Segev A, Guetta V, Hod H, Rosenberg

N, Matetzky S.

Early Platelet Response to Thienopyridine Loading in ST-Elevation Acute Myocardial

Infarction at the Time of Primary Angioplasty: Predictors and Effect on Myocardial

Reperfusion


of 93


58) Fefer P, Kopel E, Gannot S, Kuchkina K, Elian D, Raanani E, Guetta V, Goldenberg I,

Segev A.

59) Higher SYNTAX Score is Not Predictive of Late Mortality in "Real-world" Patients

with Multivessel Coronary Artery Disease Undergoing Coronary Artery Bypass Grafting


60) Sabbag A, Matetzky S, Gottlieb S, Atar S, Goldenberg I, Segev A.

Recent Temporal Trends in the Presentation, Management and Outcome of Women

Hospitalized with Acute Coronary Syndromes


61) Balmor R, Segal M, Fefer P, Buber J, Ben-Zekry S, DiSegni E, Ben-Dov I, Segev A.

The Significance of Ventricular Septal Flattening in Patients with Suspected Pulmonary

Hypertension and Preserved Left Ventricular Function


62) Kogan A, Nachum E, Segev A, Orlov B, Shinfeld A, Sternik L, Guetta V, Malachy A,

Raanani E.

Incidence of Acute Kidney Injury in the Patients Undergoing Surgical TAVI


63) Medvedofsky D, Klempner R, Fefer P, Hay I, Guetta V, Goldenberg I, Segev A.

Pulmonary Arterial Hypertension Pre- and Post-Transcatheter Aortic Valve

Implantation


64) Hamdan A, Konen E, Goitein O, Raanani E, Segev A, Eldar M, Guetta V.

Coronary Computed Tomography Angiography for Detection of Coronary Artery

Stenosis in Patients Undergoing Transcatheter Aortic Valve Implantation: Feasibility

and Diagnostic Performance.



Guetta V, Ben-Dov I, Segev A.

Exercise Hemodynamics may Enhance the Diagnosis of Diastolic Dysfunction Among

Patients with Pulmonary Hypertension. Ian Kellerman Young Investigator Award

Competition.


of 93

The 61st Annual Meeting of the Israel Heart Society, 2014, Tel Aviv, Israel

66) Sabbag A, Matetzky S, Gottlieb S, Atar S, Zahger D, Iakobishvili Z, Roth A, Guetta V,

Goldenberg I, Segev A.

Nation-Wide Real-Life Implementation of Primary Percutaneous Coronary

Intervention Strategy Improves Survival in Patients with ST-Elevation Myocardial

Infarction – A Decade Long Perspective from the Acute Coronary Syndrome Israeli

Surveys (ACSIS).


67) Hamdan A, Guetta V, Konen E, Raanani E, Klempfner R, Segev A, Goitein O,

Medvedovsky D, Eldar M, Schwammenthal E.

Computed-tomographic Assessment of Membranous Septal Anatomy for

Risk Prediction of Atrioventricular Block Associated with Transcatheter Aortic Balloon

Expandable Valve Implantation.


68) Nachum E, Lagah S, Segev A, Shinfeld A, Levin S, Hay I, Hamdan A, Guetta V,

Raanani E, Spiegelstein D.

Trans-catheter Aortic Valve Implantation: Early and Mid-term Results of Trans-apical,

Trans-axillary and Trans-aortic Approaches.


69) Fefer P, Gannot S, Kochkina K, Maor E, Matetzky S, Raanani E, Guetta V, Segev A.

Impact of Coronary Chronic Total Occlusions on Long-Term Mortality in Patients

Undergoing Coronary Artery Bypass Grafting.


70) Nachum E, Shinfeld A, Preisman S, Segev A, Guetta V, Fefer P, Hay I, Barbash I,

Raanani E, Spiegelstein D.

Transapical Trans-catheter Valve-in-Valve Implantation for Failed Mitral Valve

Bioprosthesis.


71) Sabbag A, Koifman E, Segev A, Fefer P, Medvedovsky D, Hamdan A, Hay I, Raanani

E, Barbash I, Spiegelstein D, Goldenberg I, Guetta V.

Chronic Kidney Disease and Acute Kidney Injury in Severe Aortic Stenosis

Patients Undergoing Transcatheter Aortic Valve Implantation.


of 93


72) Erez A, Segev A, Medvedofsky D, Fefer P, Raanani E, Goldenberg I, Guetta V.

Factors Affecting Survival in Men versus Women Following Trans-Catheter Aortic

Valve Implantation.


73) Kolker S, Moriel M, Matetzky S, Segev A, Shlomo N, Leitersdorf E, Goldenberg I,

Tzivoni D, Weisz G, Gottlieb S.

Association Between Statin Pre-Treatment and LDL-C Levels on the Presentation of

Patients with STEMI: Data from the ACS Israeli Survey (ACSIS) 2002-2010.

The 62nd Annual Meeting of the Israel Heart Society, 2015, Tel Aviv, Israel

74) Barbash I, Finkelstein A, Barsheshet A, Segev A, Halkin A, Assali A, Ben Gal Y,

Vaknin-Assa H, Fefer P, Sagie A, Guetta V, Kornowski R.

Improved Outcomes Following TAVI for Aortic Stenosis in Low and Intermediate Risk

vs. High Risk Patients: Results from a Multi-Center Israeli TAVI Registry.


75) Nachum E, Spiegelstein D, Segev A, Barbash I, Guetta V, Sternik L, Orlov B, Levin S,

Raanani E, Kogan A.

"Fast-Track" Pathway in the High Risk Patients Underwent Surgical Transcatheter

Valve Implantation (TAVI).


76) Regev E, Barbash I, Fefer P, Fink N, Mazin I, Erez A, Berkovitch A, Grossman Y, Maor

E, Hamdan A, Hay I, Spiegelstien D, Guetta V, Goldenberg I, Segev A.

Does Increased Valvulo-Arterial Impedance Contribute to Long-Term Outcome in

Patients Undergoing Transcatheter Aortic Valve Implantation?


77) Shaviv E, Goitein O, Konen E, Shwammenthal E, Segev A, Barbash I, Fefer P, Hay I,

Guetta V, Hamdan A.

Gender Differences in Computed Tomography Measurements before Transcatheter

Aortic Valve Implantation.



of 93

78) Mazin I, Nof E, Segev A, Bar-Lev D, Guetta V, Lipchenca I, Fefer P, Gurevitz O, Fink

N, Bogdan S, Erez A, Regev E, Berkovitch A, Grossman Y, Maor E, Hamdan A,

Goldenberg I, Hay I, Spiegelstien D, Barbash I, Eldar M, Glikson M, Beinart R.

Gender Related Differences in Procedural Conduction Defects and Permanent

Pacemaker Recipients Post Transcatherer Aortic Valve Replacement.


79) Mazin I, Nof E, Guetta V, Bar-Lev D, Segev A, Lipchenca I, Barbash I, Gurevitz O,

Fefer P, Sabbag A, Bogdan S, Goldenberg I, Regev E, Fink N, Erez E, Berkovitch A,

Grossman Y, Maor E, Hamdan A, Hay I, Spiegelstien D, Eldar M, Glikson M, Beinart R.

Long Term Pacemaker Dependency Following Permanent Pacemaker Implantation in

Transcathatar Aortic Valve Implantation patients.


80) Maor E, Khalaily N, Segel M, Segev A, Fefer P, Asher E, Guetta V, Barbash I.

Mean Pulmonary Arterial Pressure of 20-24 mmHg is not Associated with Increased

Risk of Long Term Mortality.


81) Beigel R, Iakobishvili Z, Shlomo N, Segev A, Wintrob G, Zahger D, Atar S, Alcalai R,

Gottlieb S, Asher E, Goldenberg I, Matetzky S.

Contemporary Real World Use of Novel P2Y12 Inhibitors in Patients with an Acute

Coronary Syndrome The Treatment Paradox.


82) Sabbag A, Matetzky S, Iakobishvili Z, Gottlieb S, Porter A, Moriel M, Goldenberg I,

Segev A.

Gender Differences Affecting Outcome in Young Patients (55y) with Acute Coronary

Syndromes.


83) Iakobishvili Z, Matetzky S, Sabbag A, Segev A, Atar S, Zahger D, Alcalay R,

Goldenberg I, Shlomo N, Hasdai D.

Pre-Hospital Management of Acute Coronary Syndrome in Israel (ACSIS 2013).



of 93

84) Fink N, Fefer P, Barbash I, Segev A, Regev E, Mazin I, Erez A, Berkovitch A,

Grossman Y, Maor E, Hamdan A, Ben-Zekry S, Goldenberg I, Hay I, Spiegelstein D,

Guetta V.

Septal Hypertrophy is Associated with Decreased Incidence of Para-Valvular Leak

Following Trans-femoral Aortic Valve Implantation.


85) Bogdan A, Barbash I, Segev A, Fefer P, Bogdan S, Fink N, Hamdan A, Hay I,

Spiegelstein D, Guetta V.

Albumin Predicts Long Term Mortality in Elderly Patients Undergoing Trans-catheter

Aortic Valve Implantation.


86) Kolker S, Weisz G, Moriel M, Matetzky S, Shlomo N, Segev A, Goldenberg I,

Shlezinger M, Tzivoni D, Gottlieb S.

Trends in Statin Use and Lipid Profile Among Patients Presenting with ACS Between

the Years 2002-2013, in Israel.


87) Grossman Y, Barbash I, Fefer P, Goldenberg I, Bercovitch A, Erez A, Regev E, Fink

N, Hamdan A, Hay I, Spigelstein D, Raanani R, Guetta V, Segev A.

Risk prediction of Transcatheter Aortic Valve Implantation by the Incorporation of

Albumin to Surgical Risk Scores.


88) Hamdan A, Shaviv E, Goitein O, Konen E, Segev A, Barabash I, Fefer P, Hay I, Guetta

V, Shwammenthal E.

Relationship of Left Ventricular Mass to Coronary Blood Volume in Patients

Undergoing Transcatheter Aortic valve Implantation.


89) Berkovitch A, Segev A, Barbash I, Guetta V, Grossman Y, Maor E, Erez A, Regev E,

Fink N, Mazin I, Hamdan A, Goldenberg I, Hay I, Spiegelstien D, Fefer P.

Clinical Impact of Diabetes Mellitus in Patients Undergoing Transcatheter Aortic Valve

Implantation.



of 93

90) Fink N, Guetta V, Segev A, Barbash I, Bogdan A, Hamdan A, Mazin I, Maor E, Hay I,

Spiegelstein D, Goldenberg I, Fefer P.

Corticosteroid Therapy is Associated with More Vascular Complications in Patients

Undergoing Trans-Femoral Aortic Valve Implantation.


91) Goitein O, Hamdan A, Guetta V, Konen E, Fefer P, Asher E, Hay I, Segev A, Barbash

I.

Cardiac MRI - a Tool for Myocardial Characterization of Patients with Severe Aortic

Stenosis and Impaired Left Ventricular Function.


92) Landes U, Barsheshet A, Assali A, Vaknin-Assa H, Barbash I, Guetta V, Segev A,

Finkelstein A, Halkin A, Ben-Shoshan J, Kornowski R.

Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient

Characteristics, Procedural Issues and Clinical Outcome.

The 63rd Annual Meeting of the Israel Heart Society, 2016, Tel Aviv, Israel

93) Fink N, Segev A, Finkelstein A, Kornowski R, Barbash I, Halkin A, Assali A, Rosenbaum

Z, Steinvil A, Vaknin-Assa H, Ben Shoshan J, Fefer P, Guetta V.

Balloon Post-dilatation and Outcome among Patients Undergoing Trans Aortic Valve

Implantation.


94) Witberg G, Barbash I, Finkelstein A, Assali A, Segev A, Halkin A, Fefer P, Ben-Shoshan

J, Konigstein M, Guetta V, Kornowski R, Barsheshet A.

Aortic Valve Gradient and Mortality in Patients Undergoing Transcatheter Aortic Valve

Implantation for Severe Aortic Stenosis.


95) Nachum E, Barbash I, Guetta V, Segev A, Fefer P, Orlov B, Shinfeld A, Raanani E.

Late Hemodynamic Improvement of Mitral Prosthesis after Transcatheter Mitral Valve in

Valve Implantation.


96) Shalabi A, Barbash I, Orlov B, Lipey A, Segev A, Fefer P, Feinberg M, Kogan A, Maor E,

Guetta V, Raanani E.


of 93

Trans-catheter Valve Implantation (TAVI) Versus Sutureless Aortic Valve Replacement in

Elderly Patients.


97) Hamdan A, Shaviv E, Guetta V, Barbash I, Goitein O, Konen E, Segev A, Fefer P, Assali

A, Kornowski R, Schwammenthal E.

Left Ventricular Mass to Coronary Blood Volume Ratio in Patients with Severe Aortic

Stenosis Undergoing Transcatheter Aortic valve Implantation.


98) Zeniou V, Chen S, Gilon D, Segev A, Barbash I, Finkelstein A, Beeri R, Planer D, Shuvy

M, Lotan C, Danenberg H.

Ventricular Septal Defect as a Complication of TAVI: Mechanism and Incidence.


99) Regev E, Guetta V, Kornowski R, Finkelstein A, Orvin K, Halkin A, Landes U, Steinvil A,

Levi A, Ben Shoshan J, Barbash I, Fefer P, Segev A.

Transcatheter Aortic Valve Replacement in Patients under the Age of 70.


100) Goitein O, Komisar O, Barbash I, Guetta V, Segev A, Fefer P, Asher E, Ben Zikri S,

Berkovitz A, Hamdan A, Di Segni E, Orlov B, Konen E, Brodov Y.

High Incidence of Renal Artery Stenosis in Post TAVI Acute Kidney Injury.


101) Balmor GR, Segel M, Fefer P, Maor E, Buber J, Ben Zekry S, DiSegni E, Ben-Dov I, Segev

A.

Echocardiographic Ventricular Septal Motion Abnormalities and no Left Atrial

Enlargement are Associated with Pre-capillary Pulmonary Hypertension in Patients with

Preserved Left Ventricular Function.


102) Berkovitch A, Guetta V, Barbash I, Fink N, Regev E, Maor E, Kuperstein R, Raanani E,

Shalabi A, Matetzky S, Elian D, Feinberg M, Asher E, Segev A, Fefer P.

Transcatheter Aortic Valve Implantation in Patients with Previous Malignancy.


103) Shaviv E, Barbash I, Guetta V, Schwammenthal E, Segev A, Fefer P, Goitein O, Konen

E, Hamdan A.


of 93

Gender Differences of CT Measurements in Patients Undergoing Transcatheter Aortic

Valve Implantation: Influence on Long-Term Clinical Outcomes.


104) Berkovitch A, Fefer P, Barbash I, Fink N, Regev E, Asher E, Ben-Zekry S, Matetzky S,

Elian D, Goitein O, Brodov Y, Feinberg M, Guetta V, Segev A.

Transcatheter Aortic Valve Implantation in Patients with Large Annulus.


105) Asher E, Beigel R, Barbash I, Guetta V, Segev A, Fefer P, Elian D, Mazin I, Matetzky S.

The “Burden” of Transcatheter Aortic Valve Implantation Patients Admitted to the

Intensive Coronary Care Unit.


106) Landes U, Segev A, Barbash I, Almagor Y, Danenberg H, Jaffe R, Sharony R, Orvin

K, Levi A, Assali A, Vaknin-Assa H, Khader N, Hamdan A, Shapira Y, Raanani E, Sagie A,

Guetta V, Kornowski R.

Transcatheter treatment of degenerated bioprosthetic valves: patients

characteristics, procedural detials and outcomes – A multicenter Israeli registry.

The 64th Annual Meeting of the Israel Heart Society, 2017, Tel Aviv, Israel

107) Chernomordik F, Guetta V, Fefer P, Bercovitch A, Grossman Y, Asher E, Elian D,

Mizrahi I, Barbash IM, Segev A.

Anticoagulation after transcatheter aortic valve implantation is associated with higher

bleeding risk but no thromboembolic benefit.


108) Grossman Y, Segev A, Fefer P, Chernomordik F, Berkovitch A, Asher E, Goitein O,

Brodov Y, Elian D, Mizrahi I, Guetta V, Barbash I.

TAVI in patients who underwent mitral valve interventions.


109) Kornowski R, Roguin A, Danenberg H, Vaknin Assa H, Abergel E, Rozenbaum E,

Guetta V, Landes U, Jabara R, Merdler A, Segev A, Mosseri M, Assali A.

BIOFLOW-III Satellite – One Year Clinical Outcomes of Diabetic Patients Treated with

a Biodegradable Polymer Sirolimus-Eluting Stent and Comprehensive Medical

Surveillance



of 93

110) Berkovitch A, Mazin I, Barbash I, Fefer P, Nof E, Fink N, Beigel R, Matetzky S,

Guetta V, Segev A, Glikson M, Bienart R.

Is permanent pacing indicated in patients who develop LBBB and long PR following TAVI?


111) Helft G, Petroni T, Zaman A, Georges JL, Hammoudi N, Segev A, Le Feuvre C.

Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction in

Nonagenarians: A Multicentre Study.


112) Meitus A, Kagan S, Wieder-Finesod A, Rahav G, Barlev D, Lipchenca I, Gurevitz O,

Segev A, Beinart R, Glikson M, Nof E.

Gram Negative Bacterial Infections in CIED Infection-Related Extractions – Clinical

Course and Outcome.


113) Meitus A, Kagan A, Wieder-Finesod A, Rahav G, Barlev D, Liphcenca I, Gurevitz O,

Segev A, Beinart R, Glikson M, Nof E.

Temporary Device Implantation in CIED-Dependent Patients – Safety and Outcomes


114) Brodov Y, Konen E, Samooha D, Barbash I, DiSegni M, Guetta V, Segev A, Regev

E, Chernomordik F, Glikson M, Goitein O.

Impact of mitral annulus calcifications on risk of conduction disturbances after

transcatheter aortic valve implantation.


115) Kuperstein R, Michlin M, Mazin I, Barbash I, Guetta V, Fefer P, Segev A, Arad M,

Feinberg M, Schwammenthal E. Importance of Discordant Echocardiographic

Parameters of Lesion Severity in Patients with Symptomatic Aortic Stenosis


116) Ram E, Goldenberg I, Kassif I, Segev A, Lavee J, Shlomo N, Raanani E.

Real-lif outcomes of diabetic patients undergoing surgical or percutaneous

revascularization for multi-vessel coronary artery disease.


https://events.eventact.com/ProgramView2/Agenda/Lecture?id=171481&code=1045467





of 93

117) Zusman O, Landes U, Barbash I, Finkelstein A, Danenberg H, Segev A, Guetta V,

Orvin K, Assali A, barsheshet A, Kornowski R.

Transcatheter aortic valve implantation futility risk model: From the 4-site Israeli TAVI

registry.


118) Itzhaki Ben Zadok O, Orvin K, Finkelstein A, Barbash I, Danenberg H, Segev A,

Guetta V, Halkin A, Planer D, Bental T, Vaknin Assa H, Assali A, Barsheshet A, Kornowski

R.

Sex-related differences in clinical characteristics and outcomes of patients undergoing

transcatheter aortic valve implantation – Data from the Israeli TAVI registry.


119) Younis A, Orvin K, Nof E, Barbash I, Guetta V, Berkovitch A, Fefer P, Segev A,

Glikson M, Assali A, Vaknin Assa H, Kornoeski R, Beinart R.

Effects and safety of beta-blocker withdrawl among patients undergoing

transcatheter aortic valve replacement.


120) Berkovitch A, Goldenberg I, Peled Y, Berger M, Segev A, Fefer P, Maor E,

Grossman Y, Abumuch A, Younis A, Ben Zekry S, Guetta V, Barbash I.

Direct admission of selected patients to intermediate cardiology unit after TAVI is

feasible and safe.


121) Grossman Y, Silverberg D, Berkovitch A, Chernomordik F, Younis A, Asher E,

Barbash I, Halak M, Guetta V, Segev A, Fefer P.

Lomg-term outcomes of ilio-femoral stents following trans-femoral aortic valve

replacement.


122) Rozenbaum Z, Finkelstein A, Steinvil A, Halkin A, Banai S, Barbash I, Segev A,

Guetta V, Danenberg H, Orvin K, Vaknin Assa H, Assali A, Kornowski R.

Efficacy and safety of new generation transcatheter aortic valves: Insights from the

Israeli TAVI registry.



of 93

123) Chernomordik F, Asher E, Tal S, Segev A, Guetta V, Barbash I, Elian D, Fefer P,

Younis A, Mazin I, Beigel R, Matetzky S.

Comparison of platelet inhibition in patients with STEMI vs. NSTEMI after a loading

dose of swallowed vs. chewed ticagrelor.


124) Tomer O, Falah B, Segev A, Barbash IM, Vaknin-Assa H, Kornowski R, Halkin

A, Finkelstein A, Perlman G, Danenberg H.

Alternative vascular access for Transcatheter Aortic Valve Replacement (TAVR),

analysis from the Israeli transcatheter aortic valve replacement registry

The 67th Annual Meeting of the Israel Heart Society, 2020, Virtual, Israel

125) Berkovitch A, Segev A, Maor E, Sedaghat A, Finkelstein A, Saccocci M, Kornowski

R, Latib A, De la Torre Hernandez JM, Søndergaard L, Mylotte D, van Royen N, Zaman

AG, Robert P, Sinning JM, Steinvil A, Maisano F, Orvin K, Lannopollo G, Hyun-Lee D, De

Backer O, Mercanti F, van der Wulp K, Shome J, Tchétché D, Barbash IM.

Clinical predictors for procedural stroke and implications for embolic protection

device during TAVR: Results from the multicenter Transcatheter Aortic valve

replacement in-hoSpital stroKe (TASK) study.


126) Itelman E, Vatury O, Kuperstein R, Ben-Zekry S, Fefer P, Barbash I, Segev

A, Klempfner R, Feinberg M, Guetta V, Maor E.

Survival of Patients with Moderate Aortic Stenosis: Propensity Score Matching

Analysis.


127) Vatury O, Itelman E, Kuperstein R, Ben-Zekry S, Fefer P, Barbash I, Segev

A, Klempfner R, Feinberg M, Guetta V, Maor E.

Effect of Right Ventricular Function and Systolic Pressure on Survival of Patients with

Tricuspid Regurgitation.


128) Asher E, Tal S, Mazin I, Guetta V, Segev A, Elian D, Barbash I, Fefer P, Beigel

R, Matetzky S.

https://program.eventact.com/Lecture/213980/4686864























of 93

Comparison of platelet inhibition in patients with acute coronary syndrome treated

with morphine vs. no morphine after a loading dose of swallowed vs. chewed

ticagrelor.


129) Berkovitch A, Segev A, Finkelstein A, Kornowski R, Danenberg H, Fefer P, Vaknin

Assa H, Konigstein M, Perlman G, Maor E, Planer D, Orvin K, Steinvil A, Shuvy

M, Halkin A, Assali AR, Guetta V, Barbash IM.

Procedural and remote outcome among patients undergoing urgent trans-catheter

aortic valve implantation


130) Maor E, Berkovitch A, Nof E, Beigel R, Fefer P, Guetta V, Segev A, Beinart

R, Matetzky S, Barbash I.

Temporal trends in conduction disturbances during hospital stay following

transcatheter aortic valve implantation (TAVI).


G. OTHER PUBLICATIONS

1) Segev A, Mekori YA.

The Cardiac Insufficiency Bisoprolol Study II. Letter.

Lancet 1999, 353:1361

2) Segev A.

Campylobacter-associated myopericarditis with ventricular arrhythmia in a young

hypothyroid patient. Letter.

Isr Med Assoc J 2011;13:128

3) Segev A, Lotan C.

The Israel Heart Society.

Circulation J 2012;76:2055-7

4) Segev A, Fefer P
















of 93

Trans-radial coronary interventions – a "win-win" for both patient and operator.

Editorial

Isr Med Assoc J 2013;15:301-2

5) Fefer P, Segev A, Guetta V

Through the eye of the needle – New approaches to treating valvular disease. Editorial

Isr Med Assoc J 2013;15:648-9

6) Barbash IM, Segev A

The plan was to replave the valve, not the kidneys.

Editorial

JACC Interven 2017;10:2076-7

INVITED LECTURES (Local Meetings):

1) Three clinical aspects of light chain myeloma. Meir Hospital Medical Grand

Rounds, Kfar-Saba, Israel. March 1998.

2) Genetics of hypertrophic cardiomyopathy and cardiac arrhytmias. Meir Hospital

Medical Grand Rounds, Kfar-Saba, Israel. January 2002.

3) Myocardial necrosis after percutaneous coronary interventions. St. Michael’s

Hospital Cardiology Grand Rounds, Toronto, Ontario. February 2003.

4) Advances in biomedical technologhies in Israel. Beth David Synagogue, Toronto,

Ontario. April 2003.

5) TAFI and perlecan – two new players in restenosis. St. Michael’s Hospital

Cardiology Research Rounds, Toronto, Ontario. January 2004.

6) Medical and scientific accomplishements from Israel. Jewish Community Center,

London, Ontario. February 2004.

7) Collagenase enzymatic degradation for the treatment of chronic total occlusions.

St. Michael’s Hospital Cardiology Research Rounds, Toronto, Ontario. May 2004.

8) Collagenase enzymatic degradation for the treatment of chronic total occlusions.

Chaim Sheba Medical Center Cardiology Rounds, Tel Hashomer, Israel. December

2004.


of 93

9) Coronary interventions in the elderly. Sheba Medical Center Lectures to the

Community ("Sheba on the morning"). May 2005.

10) Innovations in interventional Cardiology. Sheba Medical Center nurses rounds.

June 2005

11) Collagenase enzymatic degradation and augmentation of microvessels for the

treatment of chronic total occlusions. Hadassah Medical Center Cardiology

Rounds, Jerusalem, Israel. February 2006

12) Adjunctive therpies in patients undergoing primary PCI beyond glycoprotein

IIb/IIIa inhibitors. Annual meeting of the Israeli Heart Society councils for

interventional cardiology and intensive cardiac care. Tel Aviv, Israel. March 2006.

13) Update on acute coronary syndromes. Advanced course for foreign medical

graduates. Hasharon Hospital. October 2006

14) Pericardial diseases. Advanced course for foreign medical graduates. Hasharon

Hospital. October 2006

15) Acute Coronary Syndromes – Update. Advanced course for Internal Medicine

residents. Dan Acadia, Herzeliya, Nov 2006.


residents. Dan Acadia, Herzeliya, March 2007.

17) Technical strategies in CTO revascularization. 1st Israeli CTO meeting. Jerusalem,

May 2007

18) Debate – drug eluting stents in diabetics – the focus is the disease. Annual meeting

of the Israeli Heart Society council for Interventional Cardiology. Eilat, July 2007.

19) Non ST-elevation acute coronary syndromes – Update. Advanced course for

cardiology residents. Israel Heart Society. Qesaria, November 2007


residents. Dan Acadia, Herzeliya, March 2008

21) Mechanisms of restenosis. Tel Aviv University Cardiology CME course. March 2008

22) PCI in coronary artery disease – 2008 Update. Advanced course for cardiology

residents. Israel Heart Society. Qesaria, November 2008

23) Percutaneous aortic valve implantation. Point Counter Point (PCP) Meeting, The

Green House, Tel Aviv, February 2009


of 93

24) Pathophysiology of acute coronary syndromes. Interventional Cardiology course

for cath lab nurses and technicians on behalf of the Interventiona Cardiology

Working Group. Meir Hospital, March 2009

25) Coronary Anatomy. Interventional Cardiology course for cath lab nurses and

technicians on behalf of the Interventional Cardiology Working Group. Meir

Hospital, March 2009

26) When to use a DES, to whom and which stent? Lesion-based Perspective. Annual

meeting of the Israeli Heart Society WG for Interventional Cardiology. Tel-Aviv,

March 2009

27) Myocardial necrosis in patients with angiographically normal coronary arteries.

Tel Aviv University Cardiology CME course. May 2009

28) Overview of Cardiology topics. Tel Aviv University Internal Medicine CME.

Preperation Course for Internal Medicine Residents. May 2009

29) Therapeutic options for late DES failure. 6th International Meeting on

Intensive Cardiac Care, Tel-Aviv, Israel, October 2009

30) Basic coronary anatomy. Tel Aviv University Cardiology CME course. October 2009

31) Mechanisms of restenosis. Tel Aviv University Cardiology CME course. November

2009

32) Pathophysiology of atherosclerosis and acute coronary syndromes. Cardiology

course for MSc students in medical sciences, Tel-Aviv University. November 2009



34) Risk management in cardiology. Cardiology Course for 2nd year medical students -

4-year program. Sackler School of Medicine, Tel-Aviv University. December 2009.

35) Cardiac catheterization and hemodynamics. Cardiology Course for 2nd year

medical students - 4-year program. Sackler School of Medicine, Tel-Aviv

University. December 2009.

36) Overview of unprotected left main stenting. Annual meeting of the Israeli Working

Group in Interventional Cardiology. Jerusalem, Israel. February 2010

37) Update in Non-ST Elevation Acute Coronary Syndrome. Update in Cardiology day,

Israel Heart Society. Tel-Aviv, Israel. March 2010.


of 93

38) Complex PCI in patients on chronic anti-coagulation. Biotronik Focus Group,

Zurich, Switzerland, October 2010



40) Pathophysiology of atherosclerosis and acute coronary syndromes. Cardiology

course for MSc students in medical sciences, Tel-Aviv University. November 2010

41) Coagulation system and hemostasis in cardiology. Cardiology Course for 2nd year




4-year program. Sackler School of Medicine, Tel-Aviv University. December 2010




44) Mechanisms of restenosis. Tel Aviv University Cardiology CME course. Februray

2011.

45) Cardiac hemodynamics. Internal medicine grand rounds. Sheba Medical Center,

Tel Hashomer, Israel. February 2011

46) Novel procedures in interventional cardiology. Tel Aviv University Internal

Medicine CME course. April 2011

47) ACSIS 2010 - Interventional Management in ACS in Special Populations. The 58th

Annual Meeting of The Israel Heart Society, 2011, Tel-Aviv, Israel.

48) Anti-thrombotic therapy in hemophilia patients undergoing PCI. Intensive Cardiac

Care and Interventional Cardiology Working Groups Meeting, 2011, Tel Aviv, Israel

49) What's available for transradial access? The 2nd Israeli Workshop in Transradial

intervention, 2011, Jerusalem, Israel.

50) Interventional Cardiology Update 2011. Advanced course for cardiology residents.

Israel Heart Society. October 2011, Neve Ilan. Israel

51) Cardiac Hemodynamics. Cardiology Course for 4th year medical students (YAKAR).

Sackler School of Medicine, Tel-Aviv University. November 2011.



http://israel-heart.org.il/DATA/Cardio0511/A_Segev/L1.html


of 93




54) Stent Thrombosis in ther era of new anti-platelet therapies. Israel Heart Society

Scientific Meeting, January 2012, Eilat, Israel

55) A case of severe aortic stenosis and low EF. Isreal Heart Society Scientific Meeting,

January 2012, Eilat, Israel

56) Novel anti-platelets therapies. Maccabi Health Services (pharmacists). Tel Aviv,

May 2012

57) Myocardial necrosis in patients with normal coronary arteries. Tel Aviv University

Cardiology CME course. May 2012.

58) Update in Interventional Cardiology. Update day for family physician of the Israel

Heart Society, Tel Aviv, June 2012.

59) Update in percutaneous valvular interventions. Update day for family physician of

the Israel Heart Society, Tel Aviv, June 2012.

60) Update in coronary interventions. The 31st Conference for General and Family

Medicine. Tel Aviv, July 2012.

61) Interventional Cardiology Update 2012. Advanced course for cardiology residents.

Israel Heart Society. October 2012, Neve Ilan. Israel

62) The optimal mechanical adjuvant therapy during primary PCI. Acute cardiac Care

& Interventional Cardiology WGs Meeting, December 2012, Tel Aviv, Israel






65) TMVI – what is new? Annual Scientific Meeting of the Israel Heart Society,

February 2013, Maalot, Israel

66) Adjunctive mechanical therapy in primary PCI. Scientific Meeting of the Intensive

Cardiac Care WG, 2013, Tel Aviv, Israel

67) Novel anti-platelet therapies in ACS. Scientific meeting for family physicians by the

ICCU Working Group, April 2013, Hod Hasharon, Israel


of 93

68) The current diagnostic and therapeutic approach in pulmonary hypertension.

Update day for family physician of the Israel Heart Society, Ramat Gan, June 2013.

69) Update in structural cardiac interventions. Advanced course for cardiology

residents. Israel Heart Society. October 2013, Neve Ilan. Israel






72) Implementation of ESC STEMI guidelines – The view of the interventional

cardiologist. Annual Winter Meeting of the Israel Heart Society, Eilat. January 2014

73) Current STEMI management and outcome in Israel – insights from ACSIS 2013.

ACSIS day - hosted by the Working Group on Intensive Cardiac Care of the Israel

Heart Society, Ramat Gan, January 2014

74) Current experience and future directions with trans-catheter valvular

intervention. Internal Medicine Grand Rounds, Sheba Medical Center, Tel

Hashomer, January 2014

75) 2012 ESC STEMI guidelines – the view of the interventional cardiologist. Israel

Heart Society Winter Scientific Meeting, Eilat, January 2014

76) Trans-catheter aortic valve implantation – 2014 status. Update Meeting for

Directors of community clinics. Tel Aviv, June 2014

77) Cardiac Hemodynamics. CME course for cardiology residents. Tel Aviv Medical

Center. Tel Aviv, August 2014

78) Primary PCI and hypothermia in out-of-oospital sudden death survivors. Meeting

of the Acute Cardiac Care WG. Tel Aviv, September 2014

79) Update on structural cardiac interventions. Advanced course for cardiology

residents. Israel Heart Society. November 2014, Neve Ilan. Israel







of 93

82) Update – ESC Guidelines on myocardial revascularization. Winter Meeting of the

Israel Heart Society. Eilat, February 2015

83) Stroke prevention in patients with atrial fibrillation – the current role of NOACs.

The 37th Meeting of the Society of Family Physicians. Ramat Gan, July 2015.

84) Risk management in cardiology. Cardiology Course for 2nd and 4th year medical

students – 4 and 6 year program. Sackler School of Medicine, Tel-Aviv University.

December 2015

85) Update on transcatheter valvular interventions – CME course, Israel Heart Society

and Technion. April 2016

86) Future directions in trans-catheter mitral and tricuspid interventions, MEDICO

2016, Tel Aviv, May 2016

87) Update on TAVI – Preperation course for cardiology boards, Israel Heart Society,

Qesaria, November 2016

88) Debate - FFR should be used in most PCIs – Con. The Winter Meeting of the Israel

Heart Society, Feb 2017, Eilat, Israel

89) Debate - PCI is the preferred mode of revascularization in patients with significant

left main disease. Annual meeting of the Interventional Cardiology WG, March




91) Debate – TAVI is prefereed for most cases with intermediate risk aortic stenosis.

Winter meeting of the Israel Heart Society, Feb 2018, Eilat, Israel

92) Debate – PCI in diabetics with multivessel coronary heart disease. Annual meeting

of the Interventional Cardiology WG, 2019, Israel



PATENTS

1) United States Patent Serial No. 20070154555. Augmentation of intraluminal

microvessel formation to facilitate guide wire crossing in chronic total occlusions.

2) United States Patent Serial No. 2005097177. Collagenase administration to

facilitate guide wire crossing in chronic total occlusions.


of 93

REVIEWER AND EDITORIAL BOARD OF SCIENTIFIC JOURNALS:

1) Cardiovascular Research: 1999

2) Catheterization and Cardiovascular Interventions: 2003 - present

3) American Journal of Cardiology: 2003-present

4) Current Drug Targets – Cardiovascular & Haematological Disorders: 2003

5) Cardiovascular Pathology: 2004-present

6) Journal of the American College of Cardiology: 2004 – present

7) Lasers in Medical Science: 2006

8) Future-Drugs: 2007

9) Israel Medical Association Journal (IMAJ) – 2010 - present

10) European Journal of Gastroenterology and Hepatology: 2009

11) Cardiovascular Revascularization Medicine – 2012 – present

12) Annals, Academy of Medicine, Singapore – 2008 – present

13) Heart and Vessels – 2014 – present

14) Journal of Cardiovascular Medicine – 2014 – present

15) Expert Reviews in Cardiovascular Therapy – 2014 – present

16) British Medical Journal Open – 2014 – present

17) Journal of the Saudi Heart Association – 2015

18) American Heart Journal – 2015

19) CMRO – 2015

20) Heart – 2016

21) CarioRenal – 2016

22) Journal of Interventional Cardiology – Editorial Board

23) Journal of the American College of Cardiology - Cardiovascular Interventions:

2019 – present

CONSULTATION TO INDUSTRY:

1) Past Consultant, Biocontrol Ltd., Yahud, Israel

2) Past consultant, Rad Biomed incubator Ltd., Kiriat Atidim, Tel-Aviv, Israel

3) Past Director of Interventional Cardiology Forum, Starmed Ltd., Israel

(www.starmed.co.il/Forum/107)

http://www.starmed.co.il/Forum/107


of 93

4) Past Medical Director, ArioMedica Ltd. Kiriat Atidim, Tel-Aviv Medical

5) Past consultant, Top Spin Medical Ltd., Lod, Israel

6) Past Medical Director, Ovalum Ltd., Rehovot, Israel

7) Medical Advisory Board, ValtechCardio Ltd., Or-Yehuda, Israel

8) Consultant, Israel Triventures, Herzelya, Israel

9) Advisory Board, Sanofi, Israel

10) Consultant (Focus Group), Biotronik Ltd., Switzerland

11) Global Advisory Board, Medtronic Ltd, Santa Rosa, CA, USA

12) Advisory Board, Elly-Lilly Ltd, Israel

13) Advisory Board, Bayer Israel Ltd., Israel

14) Advisory Board, Astra-Zeneca Israel Ltd., Israel

15) Advisory Board, MSD Israel Ltd., Israel

16) Proctor for TAVI, Edwards LifeSciences Ltd., Europe.

17) Proctor for TAVI, Medtronic Ltd., Israel

18) Advisory Board, Pfizer Israel Ltd., Israel

19) Advisory Board, Abbott Vascular, Israel

20) Speaker (2013), Boston Scientific, Czech Republic

21) Vice-President and share holder, Matrizyme Pharma, Toronto, Canada

22) Consultant and speaker, LifetechMed, China

23) Advisory Board and speaker, Boeringher-Ingelheim, Israel

24) Advisory Board, Sanara Ventures, Israel

25) Advisory Board, MedX VC, Israel

STUDENTS & BASIC SCIENCE PROJECTS (RESIDENTS)

1) Dr. Erez Kachel, Vein graft remodeling in rabbit model, Department of Cardio-

Thoracic Surgery, Chaim Sheba Medical Center, 2005

2) Dr. Basheer Sheich-Yosef, Effects of statins on vein graft remodeling in a rabbit

model, Department of Cardio-Thoracic Surgery, Chaim Sheba Medical Center,

2005-2006

3) Dr. Ronen Gingy Balmor, Role of exercise during right heart catheterization in the

diagnosis of diastolic heart failure in patients with pulmonary hypertension,

Department of Pulmonology, Chaim Sheba Medical Center, 2012


of 93

4) Dr. Noam Fink, Revascularization strategies in patients with multivessel disease,

The Heart Center, Chaim Sheba Medical Center, 2014-15

5) Orly Kohanov and Dr. Yoseph Danieli, Temporal trends in the management and

outcome of women with acute coronary syndrome, MHA thesis, Bar-Ilan

University, 2012-13

6) Dr. Avi Sabbag, Gender differences in the management and outcomes of young

patients with acute coronary syndromes, The Heart Center, Chaim Sheba Medical

Center, 2015

7) Dr. Yoni Grossman, The incorporation of baseline albumin to traditional risk score

improves risk prediction in patients undergoing transcatheter aortic valve

implantation, The Heart Center, Chaim Sheba Medical Center, 2016

8) Dr. Michael Kogan, Outcome of bleeding in patients undergoing PCI on dual anti-

platelet therapy, The Heart Center, Chaim Sheba Medical Center, 2018

9) Dr. Alon Israeli, MSc Thesis in Epidemiology, Sackler School of Medicine, Tel Aviv

University, 2020

November 10, 2020 Curriculum Vitae

Documents

Transcript of November 10, 2020 Curriculum Vitae